US20160174603A1 - Electronic Vapor Liquid Composition and Method of Use - Google Patents
Electronic Vapor Liquid Composition and Method of Use Download PDFInfo
- Publication number
- US20160174603A1 US20160174603A1 US14/581,179 US201414581179A US2016174603A1 US 20160174603 A1 US20160174603 A1 US 20160174603A1 US 201414581179 A US201414581179 A US 201414581179A US 2016174603 A1 US2016174603 A1 US 2016174603A1
- Authority
- US
- United States
- Prior art keywords
- herbal
- leonurus
- vaporizing
- present
- salvia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000007788 liquid Substances 0.000 title claims abstract description 58
- 238000000034 method Methods 0.000 title claims description 17
- 239000000203 mixture Substances 0.000 title abstract description 57
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims abstract description 54
- 230000008016 vaporization Effects 0.000 claims abstract description 42
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 36
- 241000680659 Mitragyna speciosa Species 0.000 claims abstract description 29
- 244000253077 Leonotis leonurus Species 0.000 claims abstract description 25
- 241000220645 Leonotis nepetifolia Species 0.000 claims abstract description 25
- 240000005546 Piper methysticum Species 0.000 claims abstract description 25
- 235000016787 Piper methysticum Nutrition 0.000 claims abstract description 25
- 240000000143 Turnera diffusa Species 0.000 claims abstract description 25
- 235000004952 turnera diffusa Nutrition 0.000 claims abstract description 25
- 239000003571 electronic cigarette Substances 0.000 claims abstract description 21
- 241001251432 Heimia salicifolia Species 0.000 claims abstract description 20
- 235000003261 Artemisia vulgaris Nutrition 0.000 claims abstract description 19
- 241000557172 Stylophorum diphyllum Species 0.000 claims abstract description 19
- 244000007853 Sarothamnus scoparius Species 0.000 claims abstract description 18
- 235000011187 glycerol Nutrition 0.000 claims abstract description 18
- 235000013311 vegetables Nutrition 0.000 claims abstract description 18
- 235000017309 Hypericum perforatum Nutrition 0.000 claims abstract description 17
- 244000141009 Hypericum perforatum Species 0.000 claims abstract description 17
- 240000000377 Tussilago farfara Species 0.000 claims abstract description 17
- 235000004869 Tussilago farfara Nutrition 0.000 claims abstract description 17
- 235000002195 Nymphaea caerulea Nutrition 0.000 claims abstract description 15
- 240000009085 Nymphaea caerulea Species 0.000 claims abstract description 15
- 235000011771 Salvia divinorum Nutrition 0.000 claims abstract description 14
- 241001136613 Salvia divinorum Species 0.000 claims abstract description 14
- 239000000284 extract Substances 0.000 claims abstract description 14
- 240000005993 Lactuca saligna Species 0.000 claims abstract description 13
- 235000003127 Lactuca serriola Nutrition 0.000 claims abstract description 13
- 241000207929 Scutellaria Species 0.000 claims abstract description 13
- 240000006891 Artemisia vulgaris Species 0.000 claims abstract description 12
- 241001648652 Croton ovalifolius Species 0.000 claims abstract description 12
- 235000013832 Valeriana officinalis Nutrition 0.000 claims abstract description 12
- 244000126014 Valeriana officinalis Species 0.000 claims abstract description 12
- 239000000843 powder Substances 0.000 claims abstract description 12
- 235000016788 valerian Nutrition 0.000 claims abstract description 12
- 241001077823 Calea Species 0.000 claims abstract description 11
- 244000001381 Eschscholzia californica Species 0.000 claims abstract description 11
- 241001249148 Artemisia scoparia Species 0.000 claims abstract description 10
- 235000003069 Artemisia scoparia Nutrition 0.000 claims abstract description 10
- 241000207925 Leonurus Species 0.000 claims abstract description 10
- 240000002817 Leonurus sibiricus Species 0.000 claims abstract description 10
- 235000002434 Leonurus sibiricus Nutrition 0.000 claims abstract description 10
- 241001601440 Mesembryanthemum tortuosum Species 0.000 claims abstract description 10
- 241001072909 Salvia Species 0.000 claims abstract description 10
- 235000009206 Turnera diffusa Nutrition 0.000 claims abstract description 10
- 241001288212 Calea ternifolia Species 0.000 claims abstract description 9
- 235000019119 Mesembryanthemum tortuosum Nutrition 0.000 claims abstract description 9
- 235000017276 Salvia Nutrition 0.000 claims abstract description 9
- 235000010495 Sarothamnus scoparius Nutrition 0.000 claims abstract description 9
- 235000010768 Scotch broom Nutrition 0.000 claims abstract description 9
- 240000002913 Trifolium pratense Species 0.000 claims abstract description 9
- 239000012676 herbal extract Substances 0.000 claims abstract description 9
- 235000003826 Artemisia Nutrition 0.000 claims abstract description 8
- 241001293495 Lactuca virosa Species 0.000 claims abstract description 8
- 241000614197 Pedicularis densiflora Species 0.000 claims abstract description 8
- 241000632296 Scutellaria lateriflora Species 0.000 claims abstract description 8
- 235000009052 artemisia Nutrition 0.000 claims abstract description 8
- 235000016428 Nymphaea stellata Nutrition 0.000 claims abstract description 7
- 239000000654 additive Substances 0.000 claims description 37
- 230000000996 additive effect Effects 0.000 claims description 33
- 239000000463 material Substances 0.000 claims description 30
- 238000002156 mixing Methods 0.000 claims description 20
- 241000218182 Eschscholzia Species 0.000 claims description 15
- 244000030166 artemisia Species 0.000 claims description 7
- 230000000694 effects Effects 0.000 description 23
- 230000008901 benefit Effects 0.000 description 22
- 229930013930 alkaloid Natural products 0.000 description 19
- 239000004615 ingredient Substances 0.000 description 19
- 150000001875 compounds Chemical class 0.000 description 18
- 241000196324 Embryophyta Species 0.000 description 12
- 230000001624 sedative effect Effects 0.000 description 11
- 239000000126 substance Substances 0.000 description 10
- 230000003110 anti-inflammatory effect Effects 0.000 description 8
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 8
- OBSYBRPAKCASQB-AGQYDFLVSA-N salvinorin A Chemical compound C=1([C@H]2OC(=O)[C@@H]3CC[C@]4(C)[C@@H]([C@]3(C2)C)C(=O)[C@@H](OC(C)=O)C[C@H]4C(=O)OC)C=COC=1 OBSYBRPAKCASQB-AGQYDFLVSA-N 0.000 description 8
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 8
- OBSYBRPAKCASQB-UHFFFAOYSA-N Episalvinorin A Natural products COC(=O)C1CC(OC(C)=O)C(=O)C(C2(C3)C)C1(C)CCC2C(=O)OC3C=1C=COC=1 OBSYBRPAKCASQB-UHFFFAOYSA-N 0.000 description 7
- 239000000470 constituent Substances 0.000 description 7
- 230000002040 relaxant effect Effects 0.000 description 7
- IQXUYSXCJCVVPA-UHFFFAOYSA-N salvinorin A Natural products CC(=O)OC1CC(OC(=O)C)C2(C)CCC34CC(CC3(C)C2C1=O)(OC4=O)c5occc5 IQXUYSXCJCVVPA-UHFFFAOYSA-N 0.000 description 7
- 230000000949 anxiolytic effect Effects 0.000 description 6
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 230000002743 euphoric effect Effects 0.000 description 6
- 206010015535 Euphoric mood Diseases 0.000 description 5
- 208000002193 Pain Diseases 0.000 description 5
- 150000003797 alkaloid derivatives Chemical class 0.000 description 5
- 239000000796 flavoring agent Substances 0.000 description 5
- 235000019634 flavors Nutrition 0.000 description 5
- GUAFOGOEJLSQBT-UHFFFAOYSA-N scoparone Chemical compound C1=CC(=O)OC2=C1C=C(OC)C(OC)=C2 GUAFOGOEJLSQBT-UHFFFAOYSA-N 0.000 description 5
- 239000000932 sedative agent Substances 0.000 description 5
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 4
- DANYIYRPLHHOCZ-UHFFFAOYSA-N 5,7-dihydroxy-4'-methoxyflavone Chemical compound C1=CC(OC)=CC=C1C1=CC(=O)C2=C(O)C=C(O)C=C2O1 DANYIYRPLHHOCZ-UHFFFAOYSA-N 0.000 description 4
- WNGSUWLDMZFYNZ-UHFFFAOYSA-N Leonurine Chemical compound COC1=CC(C(=O)OCCCCN=C(N)N)=CC(OC)=C1O WNGSUWLDMZFYNZ-UHFFFAOYSA-N 0.000 description 4
- DAHIQPJTGIHDGO-IRXDYDNUSA-N Mesembrine Chemical compound C1=C(OC)C(OC)=CC=C1[C@@]1(CCC(=O)C2)[C@H]2N(C)CC1 DAHIQPJTGIHDGO-IRXDYDNUSA-N 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 239000002249 anxiolytic agent Substances 0.000 description 4
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 4
- 235000008216 herbs Nutrition 0.000 description 4
- IWBJJCOKGLUQIZ-HQKKAZOISA-N hyperforin Chemical compound OC1=C(CC=C(C)C)C(=O)[C@@]2(CC=C(C)C)C[C@H](CC=C(C)C)[C@](CCC=C(C)C)(C)[C@]1(C(=O)C(C)C)C2=O IWBJJCOKGLUQIZ-HQKKAZOISA-N 0.000 description 4
- QOVWXXKVLJOKNW-UHFFFAOYSA-N hyperforin Natural products CC(C)C(=O)C12CC(CC=C(C)C)(CC(CC=C(C)C)C1CCC=C(C)C)C(=C(CC=C(C)C)C2=O)O QOVWXXKVLJOKNW-UHFFFAOYSA-N 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- DAHIQPJTGIHDGO-UHFFFAOYSA-N mesembrine Natural products C1=C(OC)C(OC)=CC=C1C1(CCC(=O)C2)C2N(C)CC1 DAHIQPJTGIHDGO-UHFFFAOYSA-N 0.000 description 4
- 229940076279 serotonin Drugs 0.000 description 4
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 3
- WEEGYLXZBRQIMU-UHFFFAOYSA-N Eucalyptol Chemical compound C1CC2CCC1(C)OC2(C)C WEEGYLXZBRQIMU-UHFFFAOYSA-N 0.000 description 3
- XMGUZQZZMQBVFF-UHFFFAOYSA-N Isosabandin Natural products O1C(=O)C=CC2=C(OC)C(OC)=C(OCO3)C3=C21 XMGUZQZZMQBVFF-UHFFFAOYSA-N 0.000 description 3
- LELBFTMXCIIKKX-QVRQZEMUSA-N Mitragynine Chemical compound C1=CC(OC)=C2C(CCN3C[C@H]([C@H](C[C@H]33)\C(=C/OC)C(=O)OC)CC)=C3NC2=C1 LELBFTMXCIIKKX-QVRQZEMUSA-N 0.000 description 3
- LELBFTMXCIIKKX-SUCIZOKWSA-N Mitragynine Natural products C1=CC(OC)=C2C(CCN3C[C@H]([C@H](C[C@H]33)\C(=C\OC)C(=O)OC)CC)=C3NC2=C1 LELBFTMXCIIKKX-SUCIZOKWSA-N 0.000 description 3
- 206010039897 Sedation Diseases 0.000 description 3
- 244000269722 Thea sinensis Species 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000000049 anti-anxiety effect Effects 0.000 description 3
- 235000019504 cigarettes Nutrition 0.000 description 3
- WCZWUYYJZVBKDZ-VMSBZHFZSA-N cryogenine Chemical compound O([C@@H]1C[C@H](N2CCCC[C@@H]2C1)C=1C=C(C(=CC=11)OC)OC)C(=O)\C=C/C2=CC=C(O)C1=C2 WCZWUYYJZVBKDZ-VMSBZHFZSA-N 0.000 description 3
- 229960003638 dopamine Drugs 0.000 description 3
- 229930003944 flavone Natural products 0.000 description 3
- 150000002213 flavones Chemical class 0.000 description 3
- 235000011949 flavones Nutrition 0.000 description 3
- 229930003935 flavonoid Natural products 0.000 description 3
- 150000002215 flavonoids Chemical class 0.000 description 3
- 235000017173 flavonoids Nutrition 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 150000002559 kavalactones Chemical class 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 3
- 229960002748 norepinephrine Drugs 0.000 description 3
- 235000013824 polyphenols Nutrition 0.000 description 3
- 230000036280 sedation Effects 0.000 description 3
- GRWFGVWFFZKLTI-IUCAKERBSA-N (-)-α-pinene Chemical compound CC1=CC[C@@H]2C(C)(C)[C@H]1C2 GRWFGVWFFZKLTI-IUCAKERBSA-N 0.000 description 2
- LDCAQGBKMDSYGC-UHFFFAOYSA-N 4,9-dimethoxy-[1,3]dioxolo[4,5-g]chromen-6-one Chemical compound O1C(=O)C=CC2=C1C(OC)=C1OCOC1=C2OC LDCAQGBKMDSYGC-UHFFFAOYSA-N 0.000 description 2
- DKKJNZYHGRUXBS-BQYQJAHWSA-N 5,6-Dehydrokawain Chemical compound O1C(=O)C=C(OC)C=C1\C=C\C1=CC=CC=C1 DKKJNZYHGRUXBS-BQYQJAHWSA-N 0.000 description 2
- ZLGRXDWWYMFIGI-UHFFFAOYSA-N 6-Methylapigenin Chemical compound C=1C(=O)C2=C(O)C(C)=C(O)C=C2OC=1C1=CC=C(O)C=C1 ZLGRXDWWYMFIGI-UHFFFAOYSA-N 0.000 description 2
- RYENLSMHLCNXJT-CYXFISRXSA-N 7-Hydroxymitragynine Chemical compound C1=CC(OC)=C2[C@@]3(O)CCN4C[C@@H](CC)[C@@H](\C(=C/OC)C(=O)OC)C[C@H]4C3=NC2=C1 RYENLSMHLCNXJT-CYXFISRXSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241001233914 Chelidonium majus Species 0.000 description 2
- GSFDOOHGKOHDEL-UHFFFAOYSA-N Dalpanitin Natural products COc1cc(ccc1O)C2=COc3c(C4OC(CO)C(O)C(O)C4O)c(O)cc(O)c3C2=O GSFDOOHGKOHDEL-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 102000004300 GABA-A Receptors Human genes 0.000 description 2
- 108090000839 GABA-A Receptors Proteins 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- 206010019909 Hernia Diseases 0.000 description 2
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 2
- XLACUABANMZLCJ-KVJIRVJXSA-N Isovaltrate Chemical compound C([C@@]12[C@@H](OC(C)=O)C=C3[C@@H]1[C@H](OC(=O)CC(C)C)OC=C3COC(=O)CC(C)C)O2 XLACUABANMZLCJ-KVJIRVJXSA-N 0.000 description 2
- 241000207923 Lamiaceae Species 0.000 description 2
- 235000006679 Mentha X verticillata Nutrition 0.000 description 2
- 235000002899 Mentha suaveolens Nutrition 0.000 description 2
- 235000001636 Mentha x rotundifolia Nutrition 0.000 description 2
- 241000682686 Mitragyna Species 0.000 description 2
- RYENLSMHLCNXJT-UHFFFAOYSA-N Mitragynine hydroxyindolenine Natural products C1=CC(OC)=C2C3(O)CCN4CC(CC)C(C(=COC)C(=O)OC)CC4C3=NC2=C1 RYENLSMHLCNXJT-UHFFFAOYSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 2
- 244000061176 Nicotiana tabacum Species 0.000 description 2
- MGKCAFQXBAFOSW-ACJQSPJVSA-N O=C1C(CC=C(C)C)=C(O)[C@@]2(CC=C(C)C)C[C@H](CC=C(C)C)[C@](CCC=C(C)C)(C)[C@]1(C(=O)C(C)CC)C2=O Chemical compound O=C1C(CC=C(C)C)=C(O)[C@@]2(CC=C(C)C)C[C@H](CC=C(C)C)[C@](CCC=C(C)C)(C)[C@]1(C(=O)C(C)CC)C2=O MGKCAFQXBAFOSW-ACJQSPJVSA-N 0.000 description 2
- LRQKKQYUECPRMI-YHUSEBDRSA-N O=C1[C@H](O)[C@@H](C)[C@]2([C@]3(C)[C@@H]1C(C)(C)CCC3)O[C@@]1(C=COC1)CC2 Chemical compound O=C1[C@H](O)[C@@H](C)[C@]2([C@]3(C)[C@@H]1C(C)(C)CCC3)O[C@@]1(C=COC1)CC2 LRQKKQYUECPRMI-YHUSEBDRSA-N 0.000 description 2
- IPQKDIRUZHOIOM-UHFFFAOYSA-N Oroxin A Natural products OC1C(O)C(O)C(CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IPQKDIRUZHOIOM-UHFFFAOYSA-N 0.000 description 2
- YXBUQQDFTYOHQI-UHFFFAOYSA-N Pseudohypericin Chemical compound OC1=CC(O)=C2C(=O)C3=C(O)C=C(C)C4=C3C3=C2C1=C(C(O)=CC(O)=C1C2=O)C1=C3C1=C2C(O)=CC(CO)=C14 YXBUQQDFTYOHQI-UHFFFAOYSA-N 0.000 description 2
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
- XBHAJSJAMTWTMN-UHFFFAOYSA-N Sabandin Natural products C1OC2=C3C=CC(OC3=C(C(=C2O1)OC)OC)=O XBHAJSJAMTWTMN-UHFFFAOYSA-N 0.000 description 2
- 244000087757 Schoenoplectiella lateriflora Species 0.000 description 2
- YXHFXGHAELQJGK-PGPONNFDSA-N Scoparin Chemical compound C1=C(O)C(OC)=CC(C=2OC3=C([C@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)C(O)=CC(O)=C3C(=O)C=2)=C1 YXHFXGHAELQJGK-PGPONNFDSA-N 0.000 description 2
- 102000011017 Type 4 Cyclic Nucleotide Phosphodiesterases Human genes 0.000 description 2
- 108010037584 Type 4 Cyclic Nucleotide Phosphodiesterases Proteins 0.000 description 2
- WCZWUYYJZVBKDZ-FGSXEWAUSA-N Vertine Natural products O([C@@H]1C[C@H](N2CCCC[C@@H]2C1)C=1C=C(C(=CC=11)OC)OC)C(=O)C=CC2=CC=C(O)C1=C2 WCZWUYYJZVBKDZ-FGSXEWAUSA-N 0.000 description 2
- 235000009962 acacetin Nutrition 0.000 description 2
- RIISSLSXWPTKFE-UHFFFAOYSA-N adhyperforin Natural products CCC(C)C(=O)C12CC(CC=C(C)C)(CC(CC=C(C)C)C1CCC=C(C)C)C(=C(CC=C(C)C)C2=O)O RIISSLSXWPTKFE-UHFFFAOYSA-N 0.000 description 2
- 230000036626 alertness Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000001430 anti-depressive effect Effects 0.000 description 2
- 230000001142 anti-diarrhea Effects 0.000 description 2
- 230000003502 anti-nociceptive effect Effects 0.000 description 2
- 230000002921 anti-spasmodic effect Effects 0.000 description 2
- XADJWCRESPGUTB-UHFFFAOYSA-N apigenin Natural products C1=CC(O)=CC=C1C1=CC(=O)C2=CC(O)=C(O)C=C2O1 XADJWCRESPGUTB-UHFFFAOYSA-N 0.000 description 2
- 235000008714 apigenin Nutrition 0.000 description 2
- KZNIFHPLKGYRTM-UHFFFAOYSA-N apigenin Chemical compound C1=CC(O)=CC=C1C1=CC(=O)C2=C(O)C=C(O)C=C2O1 KZNIFHPLKGYRTM-UHFFFAOYSA-N 0.000 description 2
- 229940117893 apigenin Drugs 0.000 description 2
- BZKUYNBAFQJRDM-UHFFFAOYSA-N aporphine Chemical compound C12=CC=CC=C2CC2N(C)CCC3=CC=CC1=C32 BZKUYNBAFQJRDM-UHFFFAOYSA-N 0.000 description 2
- 239000006286 aqueous extract Substances 0.000 description 2
- IKIIZLYTISPENI-ZFORQUDYSA-N baicalin Chemical compound O1[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IKIIZLYTISPENI-ZFORQUDYSA-N 0.000 description 2
- AQHDANHUMGXSJZ-UHFFFAOYSA-N baicalin Natural products OC1C(O)C(C(O)CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 AQHDANHUMGXSJZ-UHFFFAOYSA-N 0.000 description 2
- 229960003321 baicalin Drugs 0.000 description 2
- 229940076810 beta sitosterol Drugs 0.000 description 2
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 2
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 2
- 229960001948 caffeine Drugs 0.000 description 2
- NTKNGUAZSFAKEE-UHFFFAOYSA-N capillarisin Chemical compound C=1C(=O)C2=C(O)C(OC)=C(O)C=C2OC=1OC1=CC=C(O)C=C1 NTKNGUAZSFAKEE-UHFFFAOYSA-N 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 239000000812 cholinergic antagonist Substances 0.000 description 2
- 239000000544 cholinesterase inhibitor Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 229930002882 germacranolide Natural products 0.000 description 2
- 150000003073 germacranolide derivatives Chemical class 0.000 description 2
- 230000003400 hallucinatory effect Effects 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- IRHTZOCLLONTOC-UHFFFAOYSA-N hexacosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCO IRHTZOCLLONTOC-UHFFFAOYSA-N 0.000 description 2
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000002858 neurotransmitter agent Substances 0.000 description 2
- 210000001009 nucleus accumben Anatomy 0.000 description 2
- HFPZCAJZSCWRBC-UHFFFAOYSA-N p-cymene Chemical compound CC(C)C1=CC=C(C)C=C1 HFPZCAJZSCWRBC-UHFFFAOYSA-N 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- SSKVDVBQSWQEGJ-UHFFFAOYSA-N pseudohypericin Natural products C12=C(O)C=C(O)C(C(C=3C(O)=CC(O)=C4C=33)=O)=C2C3=C2C3=C4C(C)=CC(O)=C3C(=O)C3=C(O)C=C(O)C1=C32 SSKVDVBQSWQEGJ-UHFFFAOYSA-N 0.000 description 2
- OIUBYZLTFSLSBY-HMGRVEAOSA-N quercetin 4'-O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)C=C1O OIUBYZLTFSLSBY-HMGRVEAOSA-N 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- RODXRVNMMDRFIK-UHFFFAOYSA-N scopoletin Chemical compound C1=CC(=O)OC2=C1C=C(OC)C(O)=C2 RODXRVNMMDRFIK-UHFFFAOYSA-N 0.000 description 2
- 229930004725 sesquiterpene Natural products 0.000 description 2
- 150000004354 sesquiterpene derivatives Chemical class 0.000 description 2
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 2
- 229950005143 sitosterol Drugs 0.000 description 2
- 230000007958 sleep Effects 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- MGSRCZKZVOBKFT-UHFFFAOYSA-N thymol Chemical compound CC(C)C1=CC=C(C)C=C1O MGSRCZKZVOBKFT-UHFFFAOYSA-N 0.000 description 2
- 229940098465 tincture Drugs 0.000 description 2
- HMGAHRPPRPQDAS-UHFFFAOYSA-N tricosan-2-one Chemical compound CCCCCCCCCCCCCCCCCCCCCC(C)=O HMGAHRPPRPQDAS-UHFFFAOYSA-N 0.000 description 2
- APJYDQYYACXCRM-UHFFFAOYSA-N tryptamine Chemical compound C1=CC=C2C(CCN)=CNC2=C1 APJYDQYYACXCRM-UHFFFAOYSA-N 0.000 description 2
- DZGWFCGJZKJUFP-UHFFFAOYSA-N tyramine Chemical compound NCCC1=CC=C(O)C=C1 DZGWFCGJZKJUFP-UHFFFAOYSA-N 0.000 description 2
- 239000006200 vaporizer Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- GXFZCDMWGMFGFL-KKXMJGKMSA-N (+)-Tubocurarine chloride hydrochloride Chemical compound [Cl-].[Cl-].C([C@H]1[N+](C)(C)CCC=2C=C(C(=C(OC3=CC=C(C=C3)C[C@H]3C=4C=C(C(=CC=4CC[NH+]3C)OC)O3)C=21)O)OC)C1=CC=C(O)C3=C1 GXFZCDMWGMFGFL-KKXMJGKMSA-N 0.000 description 1
- WTARULDDTDQWMU-RKDXNWHRSA-N (+)-β-pinene Chemical compound C1[C@H]2C(C)(C)[C@@H]1CCC2=C WTARULDDTDQWMU-RKDXNWHRSA-N 0.000 description 1
- NMLUOJBSAYAYEM-LIVBEALHSA-N (+-)-Corynantheidin Natural products C1=CC=C2C(CCN3C[C@H]([C@H](C[C@H]33)C(=COC)C(=O)OC)CC)=C3NC2=C1 NMLUOJBSAYAYEM-LIVBEALHSA-N 0.000 description 1
- QWVUOVZJBNQSNS-UHFFFAOYSA-N (+-)-Tropan-3endo,6exo-diol Natural products C1C(O)CC2C(O)CC1N2C QWVUOVZJBNQSNS-UHFFFAOYSA-N 0.000 description 1
- WTARULDDTDQWMU-IUCAKERBSA-N (-)-Nopinene Natural products C1[C@@H]2C(C)(C)[C@H]1CCC2=C WTARULDDTDQWMU-IUCAKERBSA-N 0.000 description 1
- NMLUOJBSAYAYEM-UHFFFAOYSA-N (-)-corynantheidine Natural products C1=CC=C2C(CCN3CC(C(CC33)C(=COC)C(=O)OC)CC)=C3NC2=C1 NMLUOJBSAYAYEM-UHFFFAOYSA-N 0.000 description 1
- 239000001100 (2S)-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)chroman-4-one Substances 0.000 description 1
- PVHCSUICRAIGCK-YJLWDSPXSA-N (2r,3r,4r,4as,8as)-4-[2-(furan-3-yl)ethyl]-2,4-dihydroxy-3,4a,8,8-tetramethyl-2,3,5,6,7,8a-hexahydronaphthalen-1-one Chemical compound C([C@]1(O)[C@@]2(C)CCCC(C)(C)[C@@H]2C(=O)[C@H](O)[C@H]1C)CC=1C=COC=1 PVHCSUICRAIGCK-YJLWDSPXSA-N 0.000 description 1
- VBBXZFLAYWAXSK-HYJCDKNOSA-N (e)-3-[(1r,4s,7r,7ar)-1-acetyloxy-3,7-dimethyl-2,4,5,6,7,7a-hexahydro-1h-inden-4-yl]-2-methylprop-2-enoic acid Chemical compound C[C@@H]1CC[C@@H](\C=C(/C)C(O)=O)C2=C(C)C[C@@H](OC(C)=O)[C@H]12 VBBXZFLAYWAXSK-HYJCDKNOSA-N 0.000 description 1
- LRQKKQYUECPRMI-UHFFFAOYSA-N 13-epi-preleoheterin Natural products CC1C(O)C(=O)C2C(C)(C)CCCC2(C)C13CCC4(COC=C4)O3 LRQKKQYUECPRMI-UHFFFAOYSA-N 0.000 description 1
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 1
- XYHKNCXZYYTLRG-UHFFFAOYSA-N 1h-imidazole-2-carbaldehyde Chemical compound O=CC1=NC=CN1 XYHKNCXZYYTLRG-UHFFFAOYSA-N 0.000 description 1
- HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 description 1
- MSYGAHOHLUJIKV-UHFFFAOYSA-N 3,5-dimethyl-1-(3-nitrophenyl)-1h-pyrazole-4-carboxylic acid ethyl ester Chemical compound CC1=C(C(=O)OCC)C(C)=NN1C1=CC=CC([N+]([O-])=O)=C1 MSYGAHOHLUJIKV-UHFFFAOYSA-N 0.000 description 1
- GWYFCOCPABKNJV-UHFFFAOYSA-M 3-Methylbutanoic acid Natural products CC(C)CC([O-])=O GWYFCOCPABKNJV-UHFFFAOYSA-M 0.000 description 1
- XWQVQSXLXAXOPJ-QNGMFEMESA-N 4-[[[6-[5-chloro-2-[[4-[[(2r)-1-methoxypropan-2-yl]amino]cyclohexyl]amino]pyridin-4-yl]pyridin-2-yl]amino]methyl]oxane-4-carbonitrile Chemical compound C1CC(N[C@H](C)COC)CCC1NC1=CC(C=2N=C(NCC3(CCOCC3)C#N)C=CC=2)=C(Cl)C=N1 XWQVQSXLXAXOPJ-QNGMFEMESA-N 0.000 description 1
- 102000049773 5-HT2A Serotonin Receptor Human genes 0.000 description 1
- YFVGIJBUXMQFOF-PJOVQGMDSA-N 5-hydroxy-2-(4-methoxyphenyl)-7-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-[[(2r,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxymethyl]oxan-2-yl]oxychromen-4-one Chemical compound C1=CC(OC)=CC=C1C(OC1=C2)=CC(=O)C1=C(O)C=C2O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@@H]([C@H](O)[C@@H](O)[C@H](C)O2)O)O1 YFVGIJBUXMQFOF-PJOVQGMDSA-N 0.000 description 1
- 102000040125 5-hydroxytryptamine receptor family Human genes 0.000 description 1
- 108091032151 5-hydroxytryptamine receptor family Proteins 0.000 description 1
- ODRDTKMYQDXVGG-UHFFFAOYSA-N 8-methoxycoumarin Natural products C1=CC(=O)OC2=C1C=CC=C2OC ODRDTKMYQDXVGG-UHFFFAOYSA-N 0.000 description 1
- 229940100578 Acetylcholinesterase inhibitor Drugs 0.000 description 1
- ZHQQRIUYLMXDPP-SSDOTTSWSA-N Actinidine Natural products C1=NC=C(C)C2=C1[C@H](C)CC2 ZHQQRIUYLMXDPP-SSDOTTSWSA-N 0.000 description 1
- 229940122614 Adenosine receptor agonist Drugs 0.000 description 1
- 244000258395 Allamanda cathartica Species 0.000 description 1
- 102100028116 Amine oxidase [flavin-containing] B Human genes 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 241000726833 Aphis cytisorum Species 0.000 description 1
- 229940122815 Aromatase inhibitor Drugs 0.000 description 1
- 241000208838 Asteraceae Species 0.000 description 1
- FXNFHKRTJBSTCS-UHFFFAOYSA-N Baicalein Natural products C=1C(=O)C=2C(O)=C(O)C(O)=CC=2OC=1C1=CC=CC=C1 FXNFHKRTJBSTCS-UHFFFAOYSA-N 0.000 description 1
- 241001252601 Blumea Species 0.000 description 1
- 229930008564 C01BA04 - Sparteine Natural products 0.000 description 1
- IXWWTVSMMIIIFZ-OZIVWOMNSA-N CCC1CN2CC[C@]3([C@@H]2C[C@@H]1\C(=C/OC)C(=O)OC)C(=O)Nc1cccc(O)c31 Chemical compound CCC1CN2CC[C@]3([C@@H]2C[C@@H]1\C(=C/OC)C(=O)OC)C(=O)Nc1cccc(O)c31 IXWWTVSMMIIIFZ-OZIVWOMNSA-N 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- HFYKETHYKFKFQE-HZPDHXFCSA-N Californidine Natural products C[N+]1(C)[C@H]2c3c(cc4OCOc4c3)C[C@@H]1c1c(cc3OCOc3c1)C2 HFYKETHYKFKFQE-HZPDHXFCSA-N 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 208000000094 Chronic Pain Diseases 0.000 description 1
- 235000007542 Cichorium intybus Nutrition 0.000 description 1
- 244000298479 Cichorium intybus Species 0.000 description 1
- 244000241235 Citrullus lanatus Species 0.000 description 1
- 235000012828 Citrullus lanatus var citroides Nutrition 0.000 description 1
- NMLUOJBSAYAYEM-QALMDFCDSA-N Corynantheidine Chemical compound C1=CC=C2C(CCN3C[C@H]([C@H](C[C@H]33)\C(=C/OC)C(=O)OC)CC)=C3NC2=C1 NMLUOJBSAYAYEM-QALMDFCDSA-N 0.000 description 1
- NMLUOJBSAYAYEM-OCUKFOPLSA-N Corynantheidine Natural products C1=CC=C2C(CCN3C[C@H]([C@H](C[C@H]33)\C(=C\OC)C(=O)OC)CC)=C3NC2=C1 NMLUOJBSAYAYEM-OCUKFOPLSA-N 0.000 description 1
- BKQVCDGQNOKQNF-KFFVICKMSA-N Corynoxine B Natural products O=C(OC)/C(=C\OC)/[C@@H]1[C@H](CC)C[N+]2[C@H]([C@@]3(C(=O)Nc4c3cccc4)CC2)C1 BKQVCDGQNOKQNF-KFFVICKMSA-N 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- WCZWUYYJZVBKDZ-KGVIQGDOSA-N Cryogenine Natural products COc1cc2[C@H]3C[C@H](C[C@H]4CCCCN34)OC(=O)C=C/c5ccc(O)c(c5)c2cc1OC WCZWUYYJZVBKDZ-KGVIQGDOSA-N 0.000 description 1
- 239000008709 Curare Substances 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- DKKJNZYHGRUXBS-UHFFFAOYSA-N Desmethoxyyangonin Natural products O1C(=O)C=C(OC)C=C1C=CC1=CC=CC=C1 DKKJNZYHGRUXBS-UHFFFAOYSA-N 0.000 description 1
- XEHFSYYAGCUKEN-UHFFFAOYSA-N Dihydroscopoletin Natural products C1CC(=O)OC2=C1C=C(OC)C(O)=C2 XEHFSYYAGCUKEN-UHFFFAOYSA-N 0.000 description 1
- JRCWYCAEAZEYNW-UHFFFAOYSA-N Epivolkenin Natural products OC1C(O)C(O)C(CO)OC1OC1(C#N)C=CC(O)C1 JRCWYCAEAZEYNW-UHFFFAOYSA-N 0.000 description 1
- WEEGYLXZBRQIMU-WAAGHKOSSA-N Eucalyptol Chemical compound C1C[C@H]2CC[C@]1(C)OC2(C)C WEEGYLXZBRQIMU-WAAGHKOSSA-N 0.000 description 1
- 241001539473 Euphoria Species 0.000 description 1
- ZCOLJUOHXJRHDI-FZHKGVQDSA-N Genistein 7-O-glucoside Natural products O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1)c1cc(O)c2C(=O)C(c3ccc(O)cc3)=COc2c1 ZCOLJUOHXJRHDI-FZHKGVQDSA-N 0.000 description 1
- CJPNHKPXZYYCME-UHFFFAOYSA-N Genistin Natural products OCC1OC(Oc2ccc(O)c3OC(=CC(=O)c23)c4ccc(O)cc4)C(O)C(O)C1O CJPNHKPXZYYCME-UHFFFAOYSA-N 0.000 description 1
- 102000017911 HTR1A Human genes 0.000 description 1
- 101150015707 HTR1A gene Proteins 0.000 description 1
- 101150104779 HTR2A gene Proteins 0.000 description 1
- 241000759815 Hebanthe paniculata Species 0.000 description 1
- 206010019851 Hepatotoxicity Diseases 0.000 description 1
- QUQPHWDTPGMPEX-UHFFFAOYSA-N Hesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(COC4C(C(O)C(O)C(C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-UHFFFAOYSA-N 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 208000004454 Hyperalgesia Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 206010061217 Infestation Diseases 0.000 description 1
- VCNYNWHVJKWJRQ-UHFFFAOYSA-N Isorhynchophylline Natural products CCC1=CN2CCC3(C2CC1C(=COC)C(=O)OC)C(=O)Nc4ccccc34 VCNYNWHVJKWJRQ-UHFFFAOYSA-N 0.000 description 1
- XLACUABANMZLCJ-UHFFFAOYSA-N Isovaltratum Natural products CC(C)CC(=O)OCC1=COC(OC(=O)CC(C)C)C2C1=CC(OC(C)=O)C21CO1 XLACUABANMZLCJ-UHFFFAOYSA-N 0.000 description 1
- XEAQIWGXBXCYFX-GUOLPTJISA-N Kawain Chemical compound C1C(OC)=CC(=O)O[C@H]1\C=C\C1=CC=CC=C1 XEAQIWGXBXCYFX-GUOLPTJISA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- CMUNUTVVOOHQPW-LURJTMIESA-N L-proline betaine Chemical compound C[N+]1(C)CCC[C@H]1C([O-])=O CMUNUTVVOOHQPW-LURJTMIESA-N 0.000 description 1
- UMVSOHBRAQTGQI-UPZYVNNASA-N Lactucopicrin Natural products O=C(O[C@@H]1[C@H]2C(=C)C(=O)O[C@@H]2[C@@H]2C(CO)=CC(=O)C2=C(C)C1)Cc1ccc(O)cc1 UMVSOHBRAQTGQI-UPZYVNNASA-N 0.000 description 1
- IYDSYBHLYZRQJL-MWHZBGGUSA-N Leoheterin Natural products C[C@@H]1[C@@H](O)C=C2C(C)(C)CCC[C@]2(C)[C@@]1(O)CCc3cocc3 IYDSYBHLYZRQJL-MWHZBGGUSA-N 0.000 description 1
- YFVGIJBUXMQFOF-SAXLCNSLSA-N Linarin Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@H](O)[C@H](Oc2cc(O)c3C(=O)C=C(c4ccc(OC)cc4)Oc3c2)O1)[C@H]1[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O1 YFVGIJBUXMQFOF-SAXLCNSLSA-N 0.000 description 1
- YXVXMURDCBMPRH-UHFFFAOYSA-N Lirinidine Natural products C1C2=CC=CC=C2C2=C(O)C(OC)=CC3=C2C1N(C)CC3 YXVXMURDCBMPRH-UHFFFAOYSA-N 0.000 description 1
- WBAVLTNIRYDCPM-YMILTQATSA-N Magnolioside Chemical compound COC1=CC=2OC(=O)C=CC=2C=C1O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O WBAVLTNIRYDCPM-YMILTQATSA-N 0.000 description 1
- JMIAZDVHNCCPDM-DAFCLMLCSA-N Mitraphylline Chemical compound O=C1NC2=CC=CC=C2[C@@]11CCN2C[C@@H]3[C@H](C)OC=C(C(=O)OC)[C@H]3C[C@H]21 JMIAZDVHNCCPDM-DAFCLMLCSA-N 0.000 description 1
- SVNPXNOASGDGHO-XJKYNJMSSA-N Mitraphylline Natural products O=C(OC)C=1[C@@H]2[C@@H]([C@@H](C)OC=1)C[N+]1[C@H]([C@@]3(C(=O)Nc4c3cccc4)CC1)C2 SVNPXNOASGDGHO-XJKYNJMSSA-N 0.000 description 1
- 108010062431 Monoamine oxidase Proteins 0.000 description 1
- 244000059220 Musa ornata Species 0.000 description 1
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 1
- ORJVQPIHKOARKV-UHFFFAOYSA-N Nuciferine Natural products C1C2=CC=CC=C2C2=C(OC)C(OC)=CC3=C2C1N(C)CC3 ORJVQPIHKOARKV-UHFFFAOYSA-N 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- YCUNGEJJOMKCGZ-UHFFFAOYSA-N Pallidiflorin Natural products C1=CC(OC)=CC=C1C1=COC2=CC=CC(O)=C2C1=O YCUNGEJJOMKCGZ-UHFFFAOYSA-N 0.000 description 1
- 235000000556 Paullinia cupana Nutrition 0.000 description 1
- 240000003444 Paullinia cupana Species 0.000 description 1
- 235000008690 Pausinystalia yohimbe Nutrition 0.000 description 1
- JPYHHZQJCSQRJY-UHFFFAOYSA-N Phloroglucinol Natural products CCC=CCC=CCC=CCC=CCCCCC(=O)C1=C(O)C=C(O)C=C1O JPYHHZQJCSQRJY-UHFFFAOYSA-N 0.000 description 1
- JLNNQCUATONMIT-CQSZACIVSA-N Pipermethystine Natural products O=C(O[C@@H]1C=CC(=O)N(C(=O)CCc2ccccc2)C1)C JLNNQCUATONMIT-CQSZACIVSA-N 0.000 description 1
- WTARULDDTDQWMU-UHFFFAOYSA-N Pseudopinene Natural products C1C2C(C)(C)C1CCC2=C WTARULDDTDQWMU-UHFFFAOYSA-N 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
- DAXYUDFNWXHGBE-KAXDATADSA-N Rhynchophylline Chemical compound O=C1NC2=CC=CC=C2[C@@]11CCN2C[C@H](CC)[C@@H](\C(=C/OC)C(=O)OC)C[C@H]21 DAXYUDFNWXHGBE-KAXDATADSA-N 0.000 description 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
- RTRPDMVGOFRVOY-UHFFFAOYSA-N Scoparin Natural products COc1cc(ccc1O)C2=CC(=O)c3c(O)cc(O)c(OC4OC(CO)C(O)C(O)C4O)c3O2 RTRPDMVGOFRVOY-UHFFFAOYSA-N 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 108010052164 Sodium Channels Proteins 0.000 description 1
- 102000018674 Sodium Channels Human genes 0.000 description 1
- FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 description 1
- 241001279009 Strychnos toxifera Species 0.000 description 1
- JRCWYCAEAZEYNW-QCMKSTAZSA-N Tetraphyllin B Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]1(C#N)C=C[C@@H](O)C1 JRCWYCAEAZEYNW-QCMKSTAZSA-N 0.000 description 1
- QCMQEZNBBPGFKQ-UHFFFAOYSA-N Thalisopynine Natural products CN1CCC2=C(OC)C(OC)=C(OC)C3=C2C1CC1=C3C=C(OC)C(O)=C1 QCMQEZNBBPGFKQ-UHFFFAOYSA-N 0.000 description 1
- 239000005844 Thymol Substances 0.000 description 1
- 102000011213 Transient receptor potential channel, canonical 6 Human genes 0.000 description 1
- 108050001421 Transient receptor potential channel, canonical 6 Proteins 0.000 description 1
- XJNQXTISSHEQKD-HIPMNCMDSA-N Valerenolic Acid Chemical compound C[C@@H]1CC[C@@H](C=C(C)C(O)=O)C2=C(C)C[C@@H](O)[C@H]12 XJNQXTISSHEQKD-HIPMNCMDSA-N 0.000 description 1
- XJNQXTISSHEQKD-UHFFFAOYSA-N Valerenolic acid Natural products CC1CCC(C=C(C)C(O)=O)C2=C(C)CC(O)C12 XJNQXTISSHEQKD-UHFFFAOYSA-N 0.000 description 1
- ZRJLCVQCZVXUFB-MRVPVSSYSA-N Valerianine Natural products O(Cc1c2c([C@H](C)CC2)cnc1)C ZRJLCVQCZVXUFB-MRVPVSSYSA-N 0.000 description 1
- ZRJLCVQCZVXUFB-QMMMGPOBSA-N Valerianine Chemical compound COCC1=CN=CC2=C1CC[C@@H]2C ZRJLCVQCZVXUFB-QMMMGPOBSA-N 0.000 description 1
- BDIAUFOIMFAIPU-KVJIRVJXSA-N Valtratum Chemical compound C([C@]12[C@@H]3C(C(=CO[C@H]3OC(=O)CC(C)C)COC(C)=O)=C[C@@H]1OC(=O)CC(C)C)O2 BDIAUFOIMFAIPU-KVJIRVJXSA-N 0.000 description 1
- HIMJIPRMECETLJ-UHFFFAOYSA-N Wogonin Natural products COc1cc(O)c(O)c2C(=O)C=C(Oc12)c3ccccc3 HIMJIPRMECETLJ-UHFFFAOYSA-N 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- VBBXZFLAYWAXSK-UHFFFAOYSA-N acetoxyvalerenic acid Natural products CC1CCC(C=C(C)C(O)=O)C2=C(C)CC(OC(C)=O)C12 VBBXZFLAYWAXSK-UHFFFAOYSA-N 0.000 description 1
- ZHQQRIUYLMXDPP-ZETCQYMHSA-N actinidine Chemical compound C1=NC=C(C)C2=C1[C@@H](C)CC2 ZHQQRIUYLMXDPP-ZETCQYMHSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001800 adrenalinergic effect Effects 0.000 description 1
- GRTOGORTSDXSFK-XJTZBENFSA-N ajmalicine Chemical compound C1=CC=C2C(CCN3C[C@@H]4[C@H](C)OC=C([C@H]4C[C@H]33)C(=O)OC)=C3NC2=C1 GRTOGORTSDXSFK-XJTZBENFSA-N 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- XCPQUQHBVVXMRQ-UHFFFAOYSA-N alpha-Fenchene Natural products C1CC2C(=C)CC1C2(C)C XCPQUQHBVVXMRQ-UHFFFAOYSA-N 0.000 description 1
- JYIJIIVLEOETIQ-UHFFFAOYSA-N alpha-Isolupanin Natural products C12CCCCN2CC2C3CCCC(=O)N3CC1C2 JYIJIIVLEOETIQ-UHFFFAOYSA-N 0.000 description 1
- SLRCCWJSBJZJBV-UHFFFAOYSA-N alpha-isosparteine Natural products C1N2CCCCC2C2CN3CCCCC3C1C2 SLRCCWJSBJZJBV-UHFFFAOYSA-N 0.000 description 1
- MVNCAPSFBDBCGF-UHFFFAOYSA-N alpha-pinene Natural products CC1=CCC23C1CC2C3(C)C MVNCAPSFBDBCGF-UHFFFAOYSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000001760 anti-analgesic effect Effects 0.000 description 1
- 230000001772 anti-angiogenic effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001078 anti-cholinergic effect Effects 0.000 description 1
- 230000003178 anti-diabetic effect Effects 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 229960000271 arbutin Drugs 0.000 description 1
- 239000003886 aromatase inhibitor Substances 0.000 description 1
- QUQPHWDTPGMPEX-UTWYECKDSA-N aurantiamarin Natural products COc1ccc(cc1O)[C@H]1CC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2O1 QUQPHWDTPGMPEX-UTWYECKDSA-N 0.000 description 1
- UDFLTIRFTXWNJO-UHFFFAOYSA-N baicalein Chemical compound O1C2=CC(=O)C(O)=C(O)C2=C(O)C=C1C1=CC=CC=C1 UDFLTIRFTXWNJO-UHFFFAOYSA-N 0.000 description 1
- 229940015301 baicalein Drugs 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N benzo-alpha-pyrone Natural products C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 1
- 229940049706 benzodiazepine Drugs 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- GWYFCOCPABKNJV-UHFFFAOYSA-N beta-methyl-butyric acid Natural products CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 description 1
- 229930006722 beta-pinene Natural products 0.000 description 1
- 102000014992 beta1-adrenergic receptor activity proteins Human genes 0.000 description 1
- 108040006808 beta1-adrenergic receptor activity proteins Proteins 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000000035 biogenic effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- VNLREARKISTOAD-SNQQTVKYSA-N butyl (1s,3r,4r,5r)-3-[(e)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]oxy-1,4,5-trihydroxycyclohexane-1-carboxylate Chemical compound C1[C@@](C(=O)OCCCC)(O)C[C@@H](O)[C@@H](O)[C@@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 VNLREARKISTOAD-SNQQTVKYSA-N 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- GLCGPUDWOPXBAY-HLRBRJAUSA-M californidine Chemical compound [Cl-].C1C2=CC=3COCC=3C=C2[C@H]2[N+](C)(C)[C@@H]1C1=CC(OCO3)=C3C=C1C2 GLCGPUDWOPXBAY-HLRBRJAUSA-M 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- VNLREARKISTOAD-ZTRFORPCSA-N chlorogenic acid butyl ester Natural products CCCCOC(=O)[C@@]1(O)C[C@@H](O)[C@H](O)[C@@H](C1)OC(=O)C=Cc2ccc(O)c(O)c2 VNLREARKISTOAD-ZTRFORPCSA-N 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 229960005233 cineole Drugs 0.000 description 1
- APSNPMVGBGZYAJ-GLOOOPAXSA-N clematine Natural products COc1cc(ccc1O)[C@@H]2CC(=O)c3c(O)cc(O[C@@H]4O[C@H](CO[C@H]5O[C@@H](C)[C@H](O)[C@@H](O)[C@H]5O)[C@@H](O)[C@H](O)[C@H]4O)cc3O2 APSNPMVGBGZYAJ-GLOOOPAXSA-N 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000010411 cooking Methods 0.000 description 1
- 235000001671 coumarin Nutrition 0.000 description 1
- 150000004775 coumarins Chemical class 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 235000021186 dishes Nutrition 0.000 description 1
- 150000004141 diterpene derivatives Chemical class 0.000 description 1
- XEAQIWGXBXCYFX-UHFFFAOYSA-N dl-kavain Natural products C1C(OC)=CC(=O)OC1C=CC1=CC=CC=C1 XEAQIWGXBXCYFX-UHFFFAOYSA-N 0.000 description 1
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 239000010642 eucalyptus oil Substances 0.000 description 1
- 229940044949 eucalyptus oil Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 229930003949 flavanone Natural products 0.000 description 1
- 150000002208 flavanones Chemical class 0.000 description 1
- 235000011981 flavanones Nutrition 0.000 description 1
- QKQLSQLKXBHUSO-CMDGGOBGSA-N flavokawain B Chemical compound COC1=CC(OC)=CC(O)=C1C(=O)\C=C\C1=CC=CC=C1 QKQLSQLKXBHUSO-CMDGGOBGSA-N 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 231100000775 forensic toxicology Toxicity 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- LCWMKIHBLJLORW-UHFFFAOYSA-N gamma-carene Natural products C1CC(=C)CC2C(C)(C)C21 LCWMKIHBLJLORW-UHFFFAOYSA-N 0.000 description 1
- ZCOLJUOHXJRHDI-CMWLGVBASA-N genistein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 ZCOLJUOHXJRHDI-CMWLGVBASA-N 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 229940068560 greater celandine Drugs 0.000 description 1
- 230000007686 hepatotoxicity Effects 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- 231100000784 hepatotoxin Toxicity 0.000 description 1
- 239000000321 herbal drug Substances 0.000 description 1
- LIIALPBMIOVAHH-UHFFFAOYSA-N herniarin Chemical compound C1=CC(=O)OC2=CC(OC)=CC=C21 LIIALPBMIOVAHH-UHFFFAOYSA-N 0.000 description 1
- JHGVLAHJJNKSAW-UHFFFAOYSA-N herniarin Natural products C1CC(=O)OC2=CC(OC)=CC=C21 JHGVLAHJJNKSAW-UHFFFAOYSA-N 0.000 description 1
- QUQPHWDTPGMPEX-QJBIFVCTSA-N hesperidin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]4[C@@H]([C@H](O)[C@@H](O)[C@H](C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-QJBIFVCTSA-N 0.000 description 1
- 229940025878 hesperidin Drugs 0.000 description 1
- VUYDGVRIQRPHFX-UHFFFAOYSA-N hesperidin Natural products COc1cc(ccc1O)C2CC(=O)c3c(O)cc(OC4OC(COC5OC(O)C(O)C(O)C5O)C(O)C(O)C4O)cc3O2 VUYDGVRIQRPHFX-UHFFFAOYSA-N 0.000 description 1
- 230000003345 hyperglycaemic effect Effects 0.000 description 1
- PHOKTTKFQUYZPI-UHFFFAOYSA-N hypericin Natural products Cc1cc(O)c2c3C(=O)C(=Cc4c(O)c5c(O)cc(O)c6c7C(=O)C(=Cc8c(C)c1c2c(c78)c(c34)c56)O)O PHOKTTKFQUYZPI-UHFFFAOYSA-N 0.000 description 1
- BTXNYTINYBABQR-UHFFFAOYSA-N hypericin Chemical compound C12=C(O)C=C(O)C(C(C=3C(O)=CC(C)=C4C=33)=O)=C2C3=C2C3=C4C(C)=CC(O)=C3C(=O)C3=C(O)C=C(O)C1=C32 BTXNYTINYBABQR-UHFFFAOYSA-N 0.000 description 1
- 229940005608 hypericin Drugs 0.000 description 1
- 208000021822 hypotensive Diseases 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 description 1
- 150000002515 isoflavone derivatives Chemical class 0.000 description 1
- 235000008696 isoflavones Nutrition 0.000 description 1
- WBAVLTNIRYDCPM-UHFFFAOYSA-N isoscopolin Natural products COC1=CC=2OC(=O)C=CC=2C=C1OC1OC(CO)C(O)C(O)C1O WBAVLTNIRYDCPM-UHFFFAOYSA-N 0.000 description 1
- SANOUVWGPVYVAV-UHFFFAOYSA-N isovaleramide Chemical compound CC(C)CC(N)=O SANOUVWGPVYVAV-UHFFFAOYSA-N 0.000 description 1
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- VJQAFLAZRVKAKM-QQUHWDOBSA-N lactucin Chemical compound O[C@@H]1CC(C)=C2C(=O)C=C(CO)[C@@H]2[C@H]2OC(=O)C(=C)[C@@H]21 VJQAFLAZRVKAKM-QQUHWDOBSA-N 0.000 description 1
- VJQAFLAZRVKAKM-UHFFFAOYSA-N lactucine Natural products OC1CC(C)=C2C(=O)C=C(CO)C2C2OC(=O)C(=C)C21 VJQAFLAZRVKAKM-UHFFFAOYSA-N 0.000 description 1
- QCDLLIUTDGNCPO-UHFFFAOYSA-N lactupicrin Natural products C12OC(=O)C(=C)C2C(O)CC(C)=C(C(C=2)=O)C1C=2COC(=O)CC1=CC=C(O)C=C1 QCDLLIUTDGNCPO-UHFFFAOYSA-N 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- FVRABHGHBLRNNR-UHFFFAOYSA-N liriodenine Natural products O=C1C=CC=c2c1cc3nccc4cc5OCOc5c2c34 FVRABHGHBLRNNR-UHFFFAOYSA-N 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- PXSNOBCUERDYST-UHFFFAOYSA-N lupanine Natural products O=C1CCCN2CC3CC(CC12)N4CCCCC34 PXSNOBCUERDYST-UHFFFAOYSA-N 0.000 description 1
- JYIJIIVLEOETIQ-XDQVBPFNSA-N lupanine Chemical compound C([C@H]12)CCCN1C[C@H]1[C@H]3CCCC(=O)N3C[C@@H]2C1 JYIJIIVLEOETIQ-XDQVBPFNSA-N 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000003446 memory effect Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 239000001525 mentha piperita l. herb oil Substances 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- BAEJBRCYKACTAA-WGUOAFTMSA-N mitragynine pseudoindoxyl Chemical group N1C2=CC=CC(OC)=C2C(=O)[C@]21CCN1C[C@@H](CC)[C@@H](\C(=C/OC)C(=O)OC)C[C@H]12 BAEJBRCYKACTAA-WGUOAFTMSA-N 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 230000009945 mood elevation Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 239000003158 myorelaxant agent Substances 0.000 description 1
- SASNBVQSOZSTPD-UHFFFAOYSA-N n-methylphenethylamine Chemical compound CNCCC1=CC=CC=C1 SASNBVQSOZSTPD-UHFFFAOYSA-N 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- ARGKVCXINMKCAZ-UHFFFAOYSA-N neohesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(CO)O3)OC3C(C(O)C(O)C(C)O3)O)=CC(O)=C2C(=O)C1 ARGKVCXINMKCAZ-UHFFFAOYSA-N 0.000 description 1
- 230000000508 neurotrophic effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000036963 noncompetitive effect Effects 0.000 description 1
- ORJVQPIHKOARKV-OAHLLOKOSA-N nuciferine Chemical compound C1C2=CC=CC=C2C2=C(OC)C(OC)=CC3=C2[C@@H]1N(C)CC3 ORJVQPIHKOARKV-OAHLLOKOSA-N 0.000 description 1
- 239000002417 nutraceutical Substances 0.000 description 1
- 235000021436 nutraceutical agent Nutrition 0.000 description 1
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 description 1
- 235000019477 peppermint oil Nutrition 0.000 description 1
- QCDYQQDYXPDABM-UHFFFAOYSA-N phloroglucinol Chemical compound OC1=CC(O)=CC(O)=C1 QCDYQQDYXPDABM-UHFFFAOYSA-N 0.000 description 1
- 229960001553 phloroglucinol Drugs 0.000 description 1
- JLNNQCUATONMIT-AWEZNQCLSA-N pipermethystine Chemical compound O=C1C=C[C@H](OC(=O)C)CN1C(=O)CCC1=CC=CC=C1 JLNNQCUATONMIT-AWEZNQCLSA-N 0.000 description 1
- 230000001242 postsynaptic effect Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- MFAYXOLUJJXHCN-IZHFEEFNSA-N prehispanolone Chemical compound C([C@]1(O2)[C@@]3(C)CCCC(C)(C)[C@@H]3CC(=O)[C@H]1C)C[C@]12COC=C1 MFAYXOLUJJXHCN-IZHFEEFNSA-N 0.000 description 1
- MFAYXOLUJJXHCN-UHFFFAOYSA-N prehispanolone Natural products CC1C(=O)CC2C(C)(C)CCCC2(C)C1(O1)CCC21COC=C2 MFAYXOLUJJXHCN-UHFFFAOYSA-N 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 229920002414 procyanidin Polymers 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 239000004089 psychotropic agent Substances 0.000 description 1
- 239000003379 purinergic P1 receptor agonist Substances 0.000 description 1
- ADRDEXBBJTUCND-UHFFFAOYSA-N pyrrolizidine Chemical class C1CCN2CCCC21 ADRDEXBBJTUCND-UHFFFAOYSA-N 0.000 description 1
- 229930002356 pyrrolizidine alkaloid Natural products 0.000 description 1
- 229960001285 quercetin Drugs 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- LJPZHJUSICYOIX-UHFFFAOYSA-N quinolizidine Chemical class C1CCCC2CCCCN21 LJPZHJUSICYOIX-UHFFFAOYSA-N 0.000 description 1
- 229930002337 quinolizidine alkaloid Natural products 0.000 description 1
- GRWFGVWFFZKLTI-UHFFFAOYSA-N rac-alpha-Pinene Natural products CC1=CCC2C(C)(C)C1C2 GRWFGVWFFZKLTI-UHFFFAOYSA-N 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- ZLQMRLSBXKQKMG-UHFFFAOYSA-N rauniticine Natural products COC(=O)C1=CC2CC3N(CCc4c3[nH]c5ccccc45)CC2C(C)O1 ZLQMRLSBXKQKMG-UHFFFAOYSA-N 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 239000003237 recreational drug Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 235000002020 sage Nutrition 0.000 description 1
- SVHDRHWULLNMQC-UHFFFAOYSA-N scoparone Natural products C1=CC(=O)OC2=C1C=C(C(=O)C)C(C(C)=O)=C2 SVHDRHWULLNMQC-UHFFFAOYSA-N 0.000 description 1
- FWYIBGHGBOVPNL-UHFFFAOYSA-N scopoletin Natural products COC=1C=C2C=CC(OC2=C(C1)O)=O FWYIBGHGBOVPNL-UHFFFAOYSA-N 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 229940126570 serotonin reuptake inhibitor Drugs 0.000 description 1
- 239000003772 serotonin uptake inhibitor Substances 0.000 description 1
- 230000002295 serotoninergic effect Effects 0.000 description 1
- 229930009674 sesquiterpene lactone Natural products 0.000 description 1
- 150000002107 sesquiterpene lactone derivatives Chemical class 0.000 description 1
- 230000009329 sexual behaviour Effects 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 229910001415 sodium ion Inorganic materials 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- SLRCCWJSBJZJBV-AJNGGQMLSA-N sparteine Chemical compound C1N2CCCC[C@H]2[C@@H]2CN3CCCC[C@H]3[C@H]1C2 SLRCCWJSBJZJBV-AJNGGQMLSA-N 0.000 description 1
- 229960001945 sparteine Drugs 0.000 description 1
- 241000894007 species Species 0.000 description 1
- CMUNUTVVOOHQPW-ZCFIWIBFSA-N stachydrine Natural products C[N+]1(C)CCC[C@@H]1C([O-])=O CMUNUTVVOOHQPW-ZCFIWIBFSA-N 0.000 description 1
- 239000010676 star anise oil Substances 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229960000790 thymol Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 235000019505 tobacco product Nutrition 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 229940125725 tranquilizer Drugs 0.000 description 1
- 239000003204 tranquilizing agent Substances 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 229960003732 tyramine Drugs 0.000 description 1
- BDIAUFOIMFAIPU-UHFFFAOYSA-N valepotriate Natural products CC(C)CC(=O)OC1C=C(C(=COC2OC(=O)CC(C)C)COC(C)=O)C2C11CO1 BDIAUFOIMFAIPU-UHFFFAOYSA-N 0.000 description 1
- FEBNTWHYQKGEIQ-SUKRRCERSA-N valerenic acid Chemical compound C[C@@H]1CC[C@@H](\C=C(/C)C(O)=O)C2=C(C)CC[C@H]12 FEBNTWHYQKGEIQ-SUKRRCERSA-N 0.000 description 1
- FUHPCDQQVWLRRY-UHFFFAOYSA-N valerenic acid Natural products CC1CCC(C=C(/C)C(=O)O)C2C1CC=C2C FUHPCDQQVWLRRY-UHFFFAOYSA-N 0.000 description 1
- 229950008559 valtrate Drugs 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- XLTFNNCXVBYBSX-UHFFFAOYSA-N wogonin Chemical compound COC1=C(O)C=C(O)C(C(C=2)=O)=C1OC=2C1=CC=CC=C1 XLTFNNCXVBYBSX-UHFFFAOYSA-N 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
- A24B—MANUFACTURE OR PREPARATION OF TOBACCO FOR SMOKING OR CHEWING; TOBACCO; SNUFF
- A24B15/00—Chemical features or treatment of tobacco; Tobacco substitutes, e.g. in liquid form
- A24B15/10—Chemical features of tobacco products or tobacco substitutes
- A24B15/16—Chemical features of tobacco products or tobacco substitutes of tobacco substitutes
-
- A—HUMAN NECESSITIES
- A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
- A24B—MANUFACTURE OR PREPARATION OF TOBACCO FOR SMOKING OR CHEWING; TOBACCO; SNUFF
- A24B15/00—Chemical features or treatment of tobacco; Tobacco substitutes, e.g. in liquid form
- A24B15/10—Chemical features of tobacco products or tobacco substitutes
- A24B15/16—Chemical features of tobacco products or tobacco substitutes of tobacco substitutes
- A24B15/167—Chemical features of tobacco products or tobacco substitutes of tobacco substitutes in liquid or vaporisable form, e.g. liquid compositions for electronic cigarettes
-
- A—HUMAN NECESSITIES
- A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
- A24B—MANUFACTURE OR PREPARATION OF TOBACCO FOR SMOKING OR CHEWING; TOBACCO; SNUFF
- A24B15/00—Chemical features or treatment of tobacco; Tobacco substitutes, e.g. in liquid form
- A24B15/18—Treatment of tobacco products or tobacco substitutes
-
- A24F47/002—
Definitions
- E-cigarettes, and e-cigarette liquid are very popular alternatives to utilizing cigarettes and other tobacco products.
- the present invention, and inventive system is a new and novel electronic cigarette liquid used in conjunction with electronic cigarettes.
- the present invention can be used to enhance effects for relaxation, euphoric, medicinal, recreational, or alternative purposes desired by a consumer. Such uses are new, and novel, benefit not offered by other products on the market.
- the present invention provides the following benefits to other e-liquids on the market place by using extracts, in a new and novel way.
- the extracts come from select herbal plants and extracts used in Native American and Eastern cultures along with chemical procedures to give a relaxant, euphoric, and/or medicinal effect to the user unlike any previous e-cigarette liquid, and the present invention utilizes non-regulated substances.
- the present invention is designed to give an e-liquid user a mood altering or enhancing effect in a safe and legal fashion.
- Zheng does this by using a chocolate extractive and tobacco (completely different ingredients from this patent filing).
- Zheng, et al, focuses on tobacco derivatives, whereas the present invention focuses on herbal and chemical infusions.
- Zheng does not disclose or contemplate the utilization of any of the additives found in the present invention.
- Patent application CN102028306 B published Jun. 27, 2012, refers to an application that calls for a mixture of ingredients into an e-cigarette blend that has a throat-rejuvenating effect using a combination of watermelon frost, peppermint oil, menthol, blumea aromatria, eucalyptus oil, and star anise oil.
- the aforementioned patent application is focused on addressing a specific condition (throat nourishment) using a specific ingredient list, whereas the present invention covers general recreational, relaxation, and general medicinal purposes using an ingredient list that is distinct and unique from the ingredients covered in that patent.
- the herbal extract can be any of the following used individually, or in combination; Karma ( sceletium tortuosum ), Blue lotus ( Nymphaea caerulea ), Salvia ( Salvia divinorum ), Kratom ( Mitragyna speciosa ), Celandine poppy ( Stylophorum diphyllum ), Mugwort ( Artemisia ), Coltsfoot leaf ( Tussilago farfara ), California poppy ( Eschscholzia californica ), Sinicuichi ( Heimia salicifolia ), St.
- John's Wort Hypericum perforatum ), Yerba lenna yesca ( Artemisia scoparia ), Calea zacatechichi ( Calea ternifolia ), Leonurus sibericus ( Leonurus sibiricus ), Wild dagga ( Leonotis leonurus ), Klip dagga ( Leonotis nepetifolia ), Damiana ( Turnera diffusa ), Kava ( Piper methysticum ), Scotch broom tops ( Cytisus scoparius ), Valarien ( Valeriana officinalis ), Indian warrior ( Pedicularis densiflora ), Wild lettuce ( Lactuca virosa ), Skullcap ( Scutellaria lateriflora ), Red Clover ( Trifolium pretense ).
- the combinations of these materials is new, novel and has never been done in use with an e-liquid application.
- a herbal additive (distinct component) is presented in a 0.001 g per 1 mL ratio (7.5%)—2.0 g per 1 mL ratio with a vaporizing base.
- a fluid mixture preferably, vegetable glycerin and/or propylene glycol mixture (common vaporizing solution) in a ratio of roughly 92% in relation to other components.
- the fluid flavoring of the e-liquid mixture comprises roughly 0.5%.
- the procedure for making the composition is as follows.
- the herbal additive (and flavor additive) is mixed with vegetable glycerin and/or propylene glycol solution.
- the mixing can be done at room temperature, heated or cooled in a preferable range of ⁇ 50 to 150° F.
- the blending can be done by using simple mixing, using an industrial blender, or other liquid mixing methods as are used in the art.
- the delivery systems for the present invention includes: electronic vaporizing, electronic cigarette, personal vaporizer, or other vaporizing methods known in the art.
- the present invention is an electronic cigarette liquid comprising a vaporizing base mixed with a herbal powder extract.
- the vaporizing base is a propylene glycol.
- the vaporizing base is a vegetable glycerin.
- said vaporizing base is mixed with said herbal powder extract at a 0.001-2.0 g per 1 mL ratio.
- the herbal extract may include members selected from the group of materials consisting of Kanna ( sceletium tortuosum ), Blue lotus ( Nymphaea caerulea ), Salvia ( Salvia divinorum ), Kratom ( Mitragyna speciosa ), Celandine poppy ( Stylophorum diphyllum ), Mugwort ( Artemisia ), Coltsfoot leaf ( Tussilago farfara ), California poppy ( Eschscholzia californica ), Sinicuichi ( Heimia salicifolia ), St.
- Kanna sceletium tortuosum
- Blue lotus Nymphaea caerulea
- Salvia Salvia divinorum
- Kratom Mitragyna speciosa
- Celandine poppy Stylophorum diphyllum
- Mugwort Artemisia
- Coltsfoot leaf Tussilago farfara
- California poppy Eschscholzia californica
- John's Wort Hypericum perforatum ), Yerba lenna yesca ( Artemisia scoparia ), Calea zacatechichi ( Calea ternifolia ), Leonurus sibericus ( Leonurus sibiricus ), Wild dagga ( Leonotis leonurus ), Klip dagga ( Leonotis nepetifolia ), Damiana ( Turnera diffusa ), Kava ( Piper methysticum ), Scotch broom tops ( Cytisus scoparius ), Valarien ( Valeriana officinalis ), Indian warrior ( Pedicularis densiflora ), Wild lettuce ( Lactuca virosa ), Skullcap ( Scutellaria lateriflora ), Red Clover ( Trifolium pretense ), and/or combinations thereof.
- the present invention comprises, a method for creating an electronic cigarette liquid comprising the steps of mixing a herbal additive with a vaporizing base wherein said base is comprised of vegetable glycerin and/or propylene glycol solution.
- the method of further comprises the step of mixing said herbal additive and said vaporizing base at a temperature between ⁇ 50 to 150° F.
- the method further comprises the steps of forming the herbal additive from a group that may include members selected from the group of materials consisting of Kanna ( sceletium tortuosum ), Blue lotus ( Nymphaea caerulea ), Salvia ( Salvia divinorum ), Kratom ( Mitragyna speciosa ), Celandine poppy ( Stylophorum diphyllum ), Mugwort ( Artemisia ), Coltsfoot leaf ( Tussilago farfara ), California poppy ( Eschscholzia californica ), Sinicuichi ( Heimia salicifolia ), St.
- Kanna sceletium tortuosum
- Blue lotus Nymphaea caerulea
- Salvia Salvia divinorum
- Kratom Mitragyna speciosa
- Celandine poppy Stylophorum diphyllum
- Mugwort Artemisia
- Coltsfoot leaf Tussilago farfara
- John's Wort Hypericum perforatum ), Yerba lenna yesca ( Artemisia scoparia ), Calea zacatechichi ( Calea ternifolia ), Leonurus sibericus ( Leonurus sibiricus ), Wild dagga ( Leonotis leonurus ), Klip dagga ( Leonotis nepetifolia ), Damiana ( Turnera diffusa ), Kava ( Piper methysticum ), Scotch broom tops ( Cytisus scoparius ), Valarien ( Valeriana officinalis ), Indian warrior ( Pedicularis densiflora ), Wild lettuce ( Lactuca virosa ), Skullcap ( Scutellaria lateriflora ), Red Clover ( Trifolium pretense ), and/or combinations thereof.
- Matture A which contains Wild Lettuce, Wild Dagga, Indian Warrior, Kava, Valerian, and Kratom
- Matture B which contains Wild Lettuce, Kratom, Skullcap, Kanna, Sinicuichi, Klip Dagga Leaf, and Blue Lotus
- Matture C which contains Leonurus sibericus , California poppy, Yerba lenna yesca, Calea zacatechichi , hernia salicifolia , Damiana, and Celandine poppy
- FIG. 1 illustrates a chart of the various plants from which the herbal additives of the present invention are derived.
- FIG. 2 illustrates a flow chart for creating one embodiment of the present invention for Mixture A.
- FIG. 3 illustrates a flow chart for creating one embodiment of the present invention for Mixture B.
- FIG. 4 illustrates a flow chart for creating one embodiment of the present invention for Mixture C.
- FIG. 5 illustrates a testing chart for the components of the present invention.
- “Herbal Additive” or “Herbal Extract” in the present application means a material selected from one or more of the following group individually, or in combination; Kanna ( sceletium tortuosum ), Blue lotus ( Nymphaea caerulea ), Salvia ( Salvia divinorum ), Kratom ( Mitragyna speciosa ), Celandine poppy ( Stylophorum diphyllum ), Mugwort ( Artemisia ), Coltsfoot leaf ( Tussilago farfara ), California poppy ( Eschscholzia californica ), Sinicuichi ( Heimia salicifolia ), St.
- John's Wort Hypericum perforatum ), Yerba lenna yesca ( Artemisia scoparia ), Calea zacatechichi ( Calea ternifolia ), Leonurus sibericus ( Leonurus sibiricus ), Wild dagga ( Leonotis leonurus ), Klip dagga ( Leonotis nepetifolia ), Damiana ( Turnera diffusa ), Kava ( Piper methysticum ), Scotch broom tops ( Cytisus scoparius ), Valarien ( Valeriana officinalis ), Indian warrior ( Pedicularis densiflora ), Wild lettuce ( Lactuca virosa ), Skullcap ( Scutellaria lateriflora ), Red Clover ( Trifolium pretense ),
- FIG. 1 illustrates a chart 100 of the various plants from which components utilized in several embodiments of the herbal compositions of the present invention are derived.
- the compositions of the present invention may include (in a variety of forms including tinctures; water, alcohol, or other liquid based forms that the herbal extract may be soluble in, including but not limited to propylene glycol and vegetable glycerin) extract powder in capsule, powder, or other form; as well as powdered plant material.
- the present invention may contain Kanna, also known as sceletium tortuosum 1.
- Mesembrine is an alkaloid present in the material Sceletium tortuosum 1, also referred to herein as “Kanna”.
- the levorotary isomer, ( ⁇ ) mesembrine is the natural form found in Kanna 4 1, This material can provide benefits to the user of the present inventive e-liquid, including but not limited to mood-elevation. It also has anxiolytic properties. 1 Harvey, A. L.; Young, L. C.; Viljoen, A.
- FIG. 1 illustrates one additive of an embodiment of the present invention which is Blue Lotus 2 ( Nymphaea caerulea ).
- the Blue Lotus 2 herb contains the alkaloids nuciferine and aporphine, which have a mildly sedating effect. This material can provide benefits to the user of the present inventive e-liquid including a relaxant effect.
- Salvia divinorum 3 The known active constituent of Salvia divinorum 3 is a trans-neoclerodane diterpenoid known as salvinorin A (chemical formula C23H28O8). This compound is present in the dried plant Salvia , at about 0.18% by volume 5 .
- Salvinorin A is not an alkaloid, (meaning it does not contain a basic nitrogen in its composition) 6 .
- Salvia divinorum 3 synthesizes and excretes its active constituent (salvinorin A) via trichomes, of the peltate-glandular morphology, located just beneath the cuticle (subcuticular) layer of the plant 7 .
- Salvinorin A is considered a dissociative, which has a long history of use as an entheogen by indigenous Mazatec cultures 8 (Valdés, 287). This material can provide a dissociative effect and pain-relief to the user of the present inventive e-liquid 9 . 5 Ott, Jonathan (1995). “Ethnopharmacognosy and Human Pharmacology of Salvia divinorum and Salvinorin A”. Curare 18 (1): 103-129. Retrieved 2007 Aug. 16. 6 Giroud, C.; Felber F.; Augsburger M. (2000). “ Salvia divinorum : an hallucinogenic mint which might become a new recreational drug in Switzerland”. Forensic Science International 112 (2): 143-150.
- one additive of the present invention is Wild Dagga ( Leonotis leonurus ) 15 .
- Leonotis leonurus 15 also known as lion's tail and wild dagga, is a plant species in the Lamiaceae (mint) family. The plant is a broadleaf evergreen large shrub native to South Africa and southern Africa, where it is very common.
- the main active component of Leonotis leonurus 15 is leonurine. This material can possess antinociceptive and anti-inflammatory properties while providing the user with mild euphoria and sedation 10 .
- one additive of the present invention is Kratom ( Mitragyna speciosa ) 5.
- Mitragyna speciosa leaves There are more than 40 compounds in Mitragyna speciosa leaves, including many alkaloids such as mitragynine, mitraphylline, 7-hydroxymitragynine, and mitragynine pseudoindoxyl.
- Other active chemicals in M. speciosa include raubasine and some yohimbe alkaloids such as corynantheidine.
- Mitragyna speciosa 5 also contains at least one alkaloid (rhynchophylline) that is a calcium channel blocker, and reduces NMDA-induced current 11 .
- LC-ESI-MS liquid chromatography-electrospray ionization mass spectrometry
- one additive of the present invention is Celandine Poppy ( Stylophorum diphyllum ) 6, the common name is derived from greater celandine ( Chelidonium majus ), a closely related European plant with similarly shaped leaves and similarly colored and shaped flowers. This material can provide benefits to the user of the present inventive e-liquid through its flavor and taste.
- one additive of the present invention which is Mugwort ( Artemisia ) 7. Mugworts 7 are used medicinally, especially in Chinese, Japanese and Korean traditional medicine, and are used as an herb to flavor food.
- Mugworts 7 were also used for plain, non-medicinal consumption; in South Korea, Mugworts 7, called Ssuk, are still used as a staple ingredient in many dishes including rice cakes and soup.
- This material can provide benefits to the user of the present inventive e-liquid by adding flavor and stimulation of circulation through pressure points in the body of a user.
- one additive of the present invention is Coltsfoot Leaf ( Tussilago farfara ) 8 .
- Tussilago farfara 8 contains pyrrolizidine alkaloids.
- This material can provide benefits to the user of the present inventive e-liquid by providing alleviation for the respiratory tract as well as alleviation for general infections and colds 14 .
- California Poppy Eschscholzia californica
- California poppy 9 leaves were used medicinally by Native Americans, and the pollen was used cosmetically.
- the seeds are used in cooking 15 .
- California Poppy 9 contains the alkaloid Californidine (which is thought to be the primary constituent responsible for the effects of California Poppy 9) 16 .
- An aqueous extract of the plant has sedative and anxiolytic action 17 .
- This material can provide benefits to the user of the present inventive e-liquid including feelings of sedation and anxiety relief.
- Sinicuichi Heimia salicifolia
- Vertine also known as cryogenine; it is regarded as the primary active component.
- Clinically demonstrated effects of Vertine include anticholinergic, anti-inflammatory, antispasmodic, hyperglycemic, hypotensive, sedative, tranquilizer, and vasodilator activity.
- This material can provide benefits to the user of the present inventive e-liquid including feelings of sedation. 15 California poppy, golden poppy, copa de oro”. Florida Museum of Natural History, University of Florida. Retrieved Apr. 9, 2012 16 Parfeinikov, S. A.; Murav'eva, D. A. (1983). “ Eschscholzia californica alkaloids”.
- one additive of the present invention is St. John's Wort ( Hypericum perforatum ) 11 abbreviated herein as “SJW”.
- SJW St. John's Wort
- Hyperforin and adhyperforin, two phloroglucinol constituents of SJW 11, are TRPC6 receptor agonists and, consequently, they induce noncompetitive reuptake inhibition of monoamines (specifically, dopamine, norepinephrine, and serotonin), GABA, and glutamate when they activate this receptor in the brain.
- Hyperforin and adhyperforin inhibit reuptake of these neurotransmitters by increasing intracellular sodium ion concentrations.
- SJW 11 is known to downregulate the ⁇ 1 adrenoceptor and upregulate postsynaptic 5-HT1A and 5-HT2A receptors, both of which are a type of serotonin receptor.
- Other compounds may also play a role in SJW's 11 effects, such compounds include: oligomeric procyanidines, flavonoids (quercetin), hypericin, and pseudohypericin 18 .
- Hyperforin the active ingredient
- SJW can provide benefits to the user of the present inventive e-liquid including anti-inflammatory and anti-depressive effects. 18 Nathan, P J (March 2001).
- Yerba Lenna Yesca ( Artemisia scoparia ) 12.
- the chemical constituents of Yerba Lenna Yesca 12 may include: Capillarisin, Chlorogenic acid butyl ester; 6,7-Dimethylesculetin; Isosabandin; Magnolioside (isoscopoletin-13-D-glucopyranoside); 7-Methoxycoumarin; 7-Methylesculetin; Sabandin A; Sabandin B; Scoparone (6,7-dimethoxycoumarin); Scopoletin; ⁇ -Sitosterol 20 .
- Artemisia scoparia 12 is an important traditional Chinese medicine.
- This material can provide benefits to the user of the present inventive e-liquid including its sedative effects.
- Calea Zacatechichi Calea ternifolia
- Chemical compounds isolated from this species may include flavones such as acacetin; and, sesquiterpene lactones such as germacranolides 21 .
- the sesquiterpenes known as caleicines and caleochromenes may be active in its effects on sleep.
- This material can provide benefits to the user of the present inventive e-liquid including its sleep remedy properties.
- Leonurus sibiricus Alkaloids isolated from Leonurus sibiricus include: Cycloleonurinine; Leoheterin; Leonurine; Leonurinine; Leuronurine; Prehispanolone; Preleoheterin; Stachydrine (“ Leonurus sibiricus ”). This material can provide benefits to the user of the present inventive e-liquid including relaxing effects. 20 Ali M S, Jahangir M, Saleem M (January 2003). “Structural distinction between sabandins A and B from Artemisia scoparia waldst. (Asteraceae)”. Nat. Prod. Res. 17 (1): 1-4. 21 Lee, I. Y., et al. (1982).
- one additive of the present invention is Klip Dagga ( Leonotis nepetifolia or L. nepetifolia ) 16.
- L. nepetifolia (Klip Dagga) 16 is related to L. leonurus 15 (wild dagga or lion's tail.)
- L. nepetifolia 's leaves are brewed as tea for fevers and coughs in Trinidad 22 .
- This material can provide benefits to the user of the present inventive e-liquid including a relaxing and anti-bacterial affect.
- Damiana Turnera diffusa 17.
- Damiana 17 contains damianin; tetraphyllin B; gonzalitosin I; arbutin; tricosan-2-one; acacetin; p-cymene; ⁇ -sitosterol; 1,8-cineole; apigenin; ⁇ -pinene; ⁇ -carotene; ⁇ -pinene; eucalyptol; tannins; thymol; and hexacosanol. 23 Damiana's 17 anxiolytic properties might be due to apigenin. It has also been shown that Damiana 17 may function as an aromatase inhibitor, which has been suggested as a possible method of action for its reputed effects.
- Kava Piper methysticum
- Kava's 18 active principal ingredients are the kavalactones. Research has suggested that kavalactones potentiate GABAA activity, but do not alter levels of dopamine and serotonin in the CNS 26 . It is thought to do this via modulating GABA activity by altering the lipid membrane structure and sodium channel function 27 . Desmethoxyyangonin, one of the six major kavalactones, is a reversible MAO-B inhibitor (Ki 280 nM) and is able to increase dopamine levels in the nucleus accumbens.
- Kavain in both enantiomeric forms, inhibits the reuptake of norepinephrine at the transporter (NAT), but not of serotonin (SERT) 29 .
- An elevated extracellular norepinephrine level in the brain may account for the reported enhancement of attention and focus.
- This material can provide to the user of the present inventive e-liquid including a euphoric effect with sedative properties in addition to increasing mental acuity. 26 Hunter, A (2006). “Kava ( Piper methysticum ) back in circulation”. Australian Centre for Complementary Medicine 25 27 Teschke, Rolf; Qiu S X; Lebot V (2011).
- Scotch broom Cytisus scoparius 19.
- the characteristic constituents of Scotch broom 19 are biogenic amines (mostly tyramine in the young shoots), flavonoids (spiraeoside and scoparoside), isoflavones and their glycosides (genistin), as well as allelopathic quinolizidine alkaloids (mostly sparteine, lupanine, scoparin and hydroxy-derivatives), which defend the plant against insect infestation and herbivory (with the exception of the resistant Aphis cytisorum ) 30 .
- This material adds flavoring and increased yellow color in the inventive e-liquid.
- Valerian Valeriana officinalis 20.
- the known compounds detected in Valerian 20 that may contribute to its method of action are: Alkaloids: actinidine, chatinine, shyanthine, valerianine, and valerine.
- Isovaleramide may be created in the extraction process; Gamma-aminobutyric acid (GABA); Isovaleric acid; Iridoids, including valepotriates: isovaltrate and valtrate.; Sesquiterpenes (contained in the Volatile oil): valerenic acid, hydroxyvalerenic acid and acetoxyvalerenic acid; and Flavanones: hesperidin, 6-methylapigenin and linarin 31 .
- This material can provide benefits to the user of the present inventive e-liquid including anti-anxiety and sedative effects.
- Indian Warrior Pedicularis densiflora
- Indian warrior 21 is used as a tea or tincture to promote healthy immune function and its ability to relax tense muscles.
- the buds and flowers of Indian Warrior 21 are often added to tea blends for their color, flavor, and relaxing properties. It is also found to be useful in the treatment of insomnia, as well as having antioxidant properties.
- This material can provide benefits to the user of the present inventive e-liquid including anti-anxiety and muscle relaxant effects.
- one additive of the present invention is Skullcap ( Scutellaria lateriflora or S. lateriflora ) 24.
- the principal phenolics in the leaves, stems, and roots of some Scutellaria species are baicalin, baicalein and wogonin.
- Baicalin has anti-inflammatory and analgesic effects in a rat model of thermal hyperalgesia 32 .
- a number of the flavones found in S. lateriflora 24 have been reported to selectively bind with high affinity to central benzodiazepine receptor sites, leading to the conclusion that the flavones exert anxiolytic and other benzodiazepine effects in rats 33 .
- This material can provide benefits to the user of the present inventive e-liquid including anti-anxiety effects.
- Lactuca virosa 22 Lactuce virosa contains flavonoids, coumarins, and N-methyl- ⁇ -phenethylamine.
- a variety of other chemical compounds have been isolated from Lactuce virosa 22.
- One of the compounds, lactucin is an adenosine receptor agonist in vitro; while another, lactucopicrin, has been shown to act as an acetylcholinesterase inhibitor in vitro 34 .
- This material can provide the user of the present inventive e-liquid sedative effect benefits.
- Red Clover Trifolium pretense 25.
- Trifolium pretense 25 is used in traditional medicine of India as deobstruent, antispasmodic, expectorant, sedative, anti-inflammatory, and antidermatosis agent 35 .
- This material can provide benefits to the user of the present inventive e-liquid including sedative effects.
- a herbal additive (distinct component) is presented in a 0.075 g per 1 mL ratio (7.5%) to the vaporizing liquid.
- a fluid mixture preferably, vegetable glycerin and/or propylene glycol mixture (common vaporizing solution) in a ratio of roughly 92%.
- the fluid flavoring comprises 0.5% of the gross volume of e-liquid.
- the procedure for making the composition is as follows.
- Herbal additive is mixed with vegetable glycerin and/or propylene glycol solution.
- the mixing can be done at room temperature, heated or cooled in the ranges of ⁇ 50 to 150° F.
- the blending can be done by using simple mixing up to using an industrial blender as is used in the art.
- the delivery systems for the present invention includes: electronic vaporizing, electronic cigarette, personal vaporizer, or other vaporizing methods known in the art.
- mixtures include, but are not limited to, mixture A 200 (which contains Wild Lettuce 22, Wild Dagga 15, Indian Warrior 21, Kava 18, Valerian 20, and Kratom 5) that has a relaxing and headache/pain-diminishing effect caused by the alkaloids in these herbs that is distinct and unique in terms of ingredients and purpose compared to other e-liquid patents.
- Mixture B 300 ( FIG. 3 ) (which contains Wild Lettuce 22, Kratom 5, Skullcap 24, Kanna 18, Sinicuichi 10, Klip Dagga Leaf 16, and Blue Lotus 2) that causes a sedated feeling with relaxation and assists in sleeping.
- Mixture C 400 ( FIG.
- Mixture A 200 a compound is created from a mixture of extracts from different herbs and components. These herbal extracts can come in various forms including a powdered form, crushed leaf form, as well as liquid form (tincture formed from herbs in a water or alcohol base).
- the product consists of different mixtures of herbal extracts to form different Herbal Additives.
- the compound 210 consists of 25% Wild Lettuce 22, 25% Wild Dagga, 20% Indian Warrior 21, 10% Kava 18, 10% Valerian 20, and 10% Kratom 5. Percentage composition is by weight in many embodiments, but can be in portions of volume or other measurements.
- the herbal additive is blended with a vaporizing solution.
- the vaporizing solution generally consists of a 50/50 blend of vegetable glycerin and propylene glycol (however the vaporizing solution can be any ratio of vegetable glycerin and propylene glycol).
- the herbal additive is then added to the vaporizing solution at a ratio of 0.075 g to 1 mL (although this ratio can vary from 0.001 to 2.0 g).
- the solution (consisting of the Herbal Additive and vaporizing solution) is blended using an industrial blender, or any other blending mechanism suitable in the art for e-liquids. The blending is typical done at slightly warmer than room temperature, but the blending can occur in temperatures between ⁇ 50-150° F. 220.
- the resulting powder-less solution is the final blend of Mixture A 200, which is put into a container for sales to an end user.
- the final blend is preferably consumed using vapor products (electronic cigarette, electronic vape pen, any device that vaporizes liquid into a smokeable vapor for the user) 230.
- the compound 310 consists of 20% Wild Lettuce, 20% Kratom 5, 15% Skullcap 24, 15% Kanna 18, 10% Sinicuichi 10, 10% Klip Dagga Leaf 16, and 10% Blue Lotus 2.
- the herbal additive is blended with a vaporizing solution.
- the vaporizing solution generally consists of a 50/50 blend of vegetable glycerin and propylene glycol (however the vaporizing solution can be any ratio of vegetable glycerin and propylene glycol).
- the herbal additive is then added to the vaporizing solution at a ratio of 0.075 g to 1 mL (although this ratio can vary from 0.001 to 2.0 g).
- the solution (consisting of the Herbal Additive and vaporizing solution) is blended using an industrial blender, or any other blending mechanism suitable in the art for e-liquids.
- the blending is typically done at slightly warmer than room temperature, but the blending can occur in temperatures between ⁇ 50-150° F. 320.
- This blend is strained over a type of filter to collect the powder residue filters known in the art, filters such as coffee filters can be used.
- the resulting powder-less solution is the final blend of Mixture B, which is put into a container for sales to an end user.
- the final blend is preferably consumed using vapor products (electronic cigarette, electronic vape pen, any device that vaporizes liquid into a smokeable vapor for the user) 330.
- the compound 410 consists of 20% Leonurus sibericus 14, 20% California Poppy 9, 20% Yerba lenna yesca 12, 20% Calea zacatechichi 13, 10% Damiana 17, and 10% Celandine Poppy 6.
- the herbal additive is blended with a vaporizing solution.
- the vaporizing solution generally consists of a 50/50 blend of vegetable glycerin and propylene glycol (however the vaporizing solution can be any ratio of vegetable glycerin and propylene glycol).
- the herbal additive is then added to the vaporizing solution at a ratio of 0.075 g to 1 mL (although this ratio can vary from 0.001 to 2.0 g).
- the solution (consisting of the Herbal Additive and vaporizing solution) is blended using an industrial blender, or any other blending mechanism suitable in the art for e-liquids.
- the blending is typically done at slightly warmer than room temperature, but the blending can occur in temperatures between ⁇ 50-150° F. 420.
- This blend is strained over a type of filter to collect the powder residue filters known in the art, other filters such as coffee filters can be used.
- the resulting powder-less solution is the final blend of Mixture C, which is put into a container for sales to an end user.
- the final blend is preferably consumed using vapor products (electronic cigarette, electronic vape pen, any device that vaporizes liquid into a smokeable vapor for the user) 430.
- the e-liquid when tested in laboratory conditions, it does not contain, or emit any substances that are controlled, or banned under current Federal and/or state regulations concerning such substances 500.
Landscapes
- Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
An e-liquid for use in electronic cigarettes which utilizes a vaporizing base (either propylene glycol, vegetable glycerin, or mixture of the two) mixed with an herbal powder extract generally at a 0.001 g-2.0 g per 1 mL ratio. The herbal extract can be any of the following: Kanna (sceletium tortuosum), Blue lotus (Nymphaea caerulea), Salvia (Salvia divinorum), Salvia eivinorm, Kratom (Mitragyna speciosa), Celandine poppy (Stylophorum diphyllum), Mugwort (Artemisia), Coltsfoot leaf (Tussilago farfara), California poppy (Eschscholzia californica), Sinicuichi (Heimia salicifolia), St. John's Wort (Hypericum perforatum), Yerba lenna yesca (Artemisia scoparia), Calea zacatechichi (Calea ternifolia), Leonurus sibericus (Leonurus sibiricus), Wild dagga (Leonotis leonurus), Klip dagga (Leonotis nepetifolia), Damiana (Turnera diffusa), Kava (Piper methysticum), Scotch broom tops (Cytisus scoparius), Valarien (Valeriana officinalis), Indian warrior (Pedicularis densiflora), Wild lettuce (Lactuca virosa), Skullcap (Scutellaria lateriflora), Red Clover (Trifolium pretense), and/or combinations therein.
Description
- Not applicable.
- Not applicable
- E-cigarettes, and e-cigarette liquid are very popular alternatives to utilizing cigarettes and other tobacco products. The present invention, and inventive system, is a new and novel electronic cigarette liquid used in conjunction with electronic cigarettes. The present invention can be used to enhance effects for relaxation, euphoric, medicinal, recreational, or alternative purposes desired by a consumer. Such uses are new, and novel, benefit not offered by other products on the market. The present invention provides the following benefits to other e-liquids on the market place by using extracts, in a new and novel way. The extracts come from select herbal plants and extracts used in Native American and Eastern cultures along with chemical procedures to give a relaxant, euphoric, and/or medicinal effect to the user unlike any previous e-cigarette liquid, and the present invention utilizes non-regulated substances. The present invention is designed to give an e-liquid user a mood altering or enhancing effect in a safe and legal fashion.
- In the prior art, there are e-cigarette liquid patents and applications that address e-liquid compositions (i.e., they refer to a composition of a mixture), however the present invention has a composition of a mixture that is unique from any of the prior art patents. By way of example, the patent application US 2013/0008457 to Zheng, et al, published Jan. 10, 2013 (“Zheng”), addresses a preparation method of e-cigarette liquid. However the present invention's composition scope covers a specific ingredient list that is distinct unique from Zheng's patent application, and also provides an effect distinctive of Zheng. Zheng's patent focuses on making e-cigarette liquid similar, in terms of aroma and taste, to actual cigarettes (a completely distinct and different purpose from the present patent filing). Zheng does this by using a chocolate extractive and tobacco (completely different ingredients from this patent filing). Zheng, et al, focuses on tobacco derivatives, whereas the present invention focuses on herbal and chemical infusions. Zheng does not disclose or contemplate the utilization of any of the additives found in the present invention.
- Patent application CN102028306 B, published Jun. 27, 2012, refers to an application that calls for a mixture of ingredients into an e-cigarette blend that has a throat-rejuvenating effect using a combination of watermelon frost, peppermint oil, menthol, blumea aromatria, eucalyptus oil, and star anise oil. The aforementioned patent application is focused on addressing a specific condition (throat nourishment) using a specific ingredient list, whereas the present invention covers general recreational, relaxation, and general medicinal purposes using an ingredient list that is distinct and unique from the ingredients covered in that patent. The patent application CN 1994159 A published on Jun. 11, 2007, references a combination of ingredients into an electronic atomized cigarette that serves as a kidney-strengthening function. That prior patent application is focused on addressing a specific purpose (kidney strengthening), a unique and different purpose as compared to the present invention. In addition, the aforementioned patent covers ingredients that are distinct and different from our ingredients (their ingredient list is more flavor and food-based whereas the present invention focuses on enhancement features). The patent application CN 101926505 A published Dec. 29, 2010, discloses a combination of ingredients for an electronic cigarette liquid using caffeine (to produce a more alert/aware effect, similar to coffee). That patent application covers a caffeine-containing substance (guarana) in the e-liquid for the purpose of making the user more alert and aware, whereas “this” or “the present” patent covers ingredients that are distinct and different from that patent's unique ingredient along with a more general recreational, relaxation, and medicinal purpose. That previous patent application, again fails to disclose or contemplate the unique ingredient list that found in the present invention.
- None of the prior art patents or applications, utilize or suggest the detailed breakout of ingredients and processes found in at least one embodiment of the present invention which comprises a combination of the following: (1) vaporizing base (either propylene glycol, vegetable glycerin, or combination of the two—and this is found in every e-cigarette liquid blend) mixed with (2) a herbal powder extract generally at a 0.001-2.0 g per 1 mL ratio. Other ratios can be utilized though. The herbal extract can be any of the following used individually, or in combination; Karma (sceletium tortuosum), Blue lotus (Nymphaea caerulea), Salvia (Salvia divinorum), Kratom (Mitragyna speciosa), Celandine poppy (Stylophorum diphyllum), Mugwort (Artemisia), Coltsfoot leaf (Tussilago farfara), California poppy (Eschscholzia californica), Sinicuichi (Heimia salicifolia), St. John's Wort (Hypericum perforatum), Yerba lenna yesca (Artemisia scoparia), Calea zacatechichi (Calea ternifolia), Leonurus sibericus (Leonurus sibiricus), Wild dagga (Leonotis leonurus), Klip dagga (Leonotis nepetifolia), Damiana (Turnera diffusa), Kava (Piper methysticum), Scotch broom tops (Cytisus scoparius), Valarien (Valeriana officinalis), Indian warrior (Pedicularis densiflora), Wild lettuce (Lactuca virosa), Skullcap (Scutellaria lateriflora), Red Clover (Trifolium pretense). The combinations of these materials is new, novel and has never been done in use with an e-liquid application.
- In one embodiment of the present invention, a herbal additive (distinct component) is presented in a 0.001 g per 1 mL ratio (7.5%)—2.0 g per 1 mL ratio with a vaporizing base. In one embodiment of the present invention there is a fluid mixture, preferably, vegetable glycerin and/or propylene glycol mixture (common vaporizing solution) in a ratio of roughly 92% in relation to other components. In one embodiment of the present invention the fluid flavoring of the e-liquid mixture comprises roughly 0.5%.
- In one embodiment of the present invention, the procedure for making the composition is as follows. The herbal additive (and flavor additive) is mixed with vegetable glycerin and/or propylene glycol solution. In several embodiments of the present invention the mixing can be done at room temperature, heated or cooled in a preferable range of −50 to 150° F. In several embodiments of the present invention the blending can be done by using simple mixing, using an industrial blender, or other liquid mixing methods as are used in the art. In many embodiments of the present invention, the delivery systems for the present invention includes: electronic vaporizing, electronic cigarette, personal vaporizer, or other vaporizing methods known in the art.
- In one embodiment, the present invention is an electronic cigarette liquid comprising a vaporizing base mixed with a herbal powder extract. In several embodiments, the vaporizing base is a propylene glycol. In several embodiments the vaporizing base is a vegetable glycerin. In several embodiments, said vaporizing base is mixed with said herbal powder extract at a 0.001-2.0 g per 1 mL ratio. In several embodiments of the present invention, the herbal extract may include members selected from the group of materials consisting of Kanna (sceletium tortuosum), Blue lotus (Nymphaea caerulea), Salvia (Salvia divinorum), Kratom (Mitragyna speciosa), Celandine poppy (Stylophorum diphyllum), Mugwort (Artemisia), Coltsfoot leaf (Tussilago farfara), California poppy (Eschscholzia californica), Sinicuichi (Heimia salicifolia), St. John's Wort (Hypericum perforatum), Yerba lenna yesca (Artemisia scoparia), Calea zacatechichi (Calea ternifolia), Leonurus sibericus (Leonurus sibiricus), Wild dagga (Leonotis leonurus), Klip dagga (Leonotis nepetifolia), Damiana (Turnera diffusa), Kava (Piper methysticum), Scotch broom tops (Cytisus scoparius), Valarien (Valeriana officinalis), Indian warrior (Pedicularis densiflora), Wild lettuce (Lactuca virosa), Skullcap (Scutellaria lateriflora), Red Clover (Trifolium pretense), and/or combinations thereof.
- In several embodiments of the present invention, the present invention comprises, a method for creating an electronic cigarette liquid comprising the steps of mixing a herbal additive with a vaporizing base wherein said base is comprised of vegetable glycerin and/or propylene glycol solution. In several embodiments of the present invention the method of further comprises the step of mixing said herbal additive and said vaporizing base at a temperature between −50 to 150° F. In several embodiments of the present invention, the method further comprises the steps of forming the herbal additive from a group that may include members selected from the group of materials consisting of Kanna (sceletium tortuosum), Blue lotus (Nymphaea caerulea), Salvia (Salvia divinorum), Kratom (Mitragyna speciosa), Celandine poppy (Stylophorum diphyllum), Mugwort (Artemisia), Coltsfoot leaf (Tussilago farfara), California poppy (Eschscholzia californica), Sinicuichi (Heimia salicifolia), St. John's Wort (Hypericum perforatum), Yerba lenna yesca (Artemisia scoparia), Calea zacatechichi (Calea ternifolia), Leonurus sibericus (Leonurus sibiricus), Wild dagga (Leonotis leonurus), Klip dagga (Leonotis nepetifolia), Damiana (Turnera diffusa), Kava (Piper methysticum), Scotch broom tops (Cytisus scoparius), Valarien (Valeriana officinalis), Indian warrior (Pedicularis densiflora), Wild lettuce (Lactuca virosa), Skullcap (Scutellaria lateriflora), Red Clover (Trifolium pretense), and/or combinations thereof.
- Several examples of successful mixtures of the present invention include “Mixture A” (which contains Wild Lettuce, Wild Dagga, Indian Warrior, Kava, Valerian, and Kratom) that has a relaxing and headache/pain-diminishing effect caused by the alkaloids in these herbs that is distinct and unique in terms of ingredients and purpose compared to other e-liquid patents; “Mixture B” (which contains Wild Lettuce, Kratom, Skullcap, Kanna, Sinicuichi, Klip Dagga Leaf, and Blue Lotus) that causes a sedated feeling with relaxation and assists in sleeping; and “Mixture C” (which contains Leonurus sibericus, California poppy, Yerba lenna yesca, Calea zacatechichi, hernia salicifolia, Damiana, and Celandine poppy) that causes a euphoric feeling with alertness.
- For a more complete understanding of the present disclosure, and the advantages thereof, reference is now made to the following descriptions to be taken in conjunction with the accompanying drawings describing specific embodiments of the disclosure, wherein:
-
FIG. 1 illustrates a chart of the various plants from which the herbal additives of the present invention are derived. -
FIG. 2 illustrates a flow chart for creating one embodiment of the present invention for Mixture A. -
FIG. 3 illustrates a flow chart for creating one embodiment of the present invention for Mixture B. -
FIG. 4 illustrates a flow chart for creating one embodiment of the present invention for Mixture C. -
FIG. 5 illustrates a testing chart for the components of the present invention. - In the following description, certain details are set forth such as specific quantities, sizes, etc., so as to provide a thorough understanding of the embodiments disclosed herein. However, it will be evident to those of ordinary skill in the art that the present disclosure may be practiced without such specific details. In many cases, details concerning such considerations and the like have been omitted inasmuch as such details are not necessary to obtain a complete understanding of the present disclosure and are within the skills of persons of ordinary skill in the relevant art.
- Referring to the drawings in general, it will be understood that the illustrations are for the purpose of describing particular embodiments of the disclosure and are not intended to be limiting thereto. Drawings are not necessarily to scale.
- While most of the terms used herein will be recognizable to those of ordinary skill in the art, it should be understood, however, that when not explicitly defined, terms should be interpreted as adopting a meaning presently accepted by those of ordinary skill in the art. In cases where the construction of a term would render it meaningless or essentially meaningless, the definition should be taken from Webster's Dictionary, 11th Edition, 2008. Definitions and/or interpretations should not be incorporated from other patent applications, patents, or publications, related or not, unless specifically stated in this specification or if the incorporation is necessary for maintaining validity. “Herbal Additive” or “Herbal Extract” in the present application means a material selected from one or more of the following group individually, or in combination; Kanna (sceletium tortuosum), Blue lotus (Nymphaea caerulea), Salvia (Salvia divinorum), Kratom (Mitragyna speciosa), Celandine poppy (Stylophorum diphyllum), Mugwort (Artemisia), Coltsfoot leaf (Tussilago farfara), California poppy (Eschscholzia californica), Sinicuichi (Heimia salicifolia), St. John's Wort (Hypericum perforatum), Yerba lenna yesca (Artemisia scoparia), Calea zacatechichi (Calea ternifolia), Leonurus sibericus (Leonurus sibiricus), Wild dagga (Leonotis leonurus), Klip dagga (Leonotis nepetifolia), Damiana (Turnera diffusa), Kava (Piper methysticum), Scotch broom tops (Cytisus scoparius), Valarien (Valeriana officinalis), Indian warrior (Pedicularis densiflora), Wild lettuce (Lactuca virosa), Skullcap (Scutellaria lateriflora), Red Clover (Trifolium pretense),
- One or more illustrative embodiments incorporating the invention disclosed herein are presented below. Applicants have created a revolutionary and novel composition of e-liquids for electronic cigarettes and the like.
-
FIG. 1 illustrates achart 100 of the various plants from which components utilized in several embodiments of the herbal compositions of the present invention are derived. The compositions of the present invention may include (in a variety of forms including tinctures; water, alcohol, or other liquid based forms that the herbal extract may be soluble in, including but not limited to propylene glycol and vegetable glycerin) extract powder in capsule, powder, or other form; as well as powdered plant material. In many embodiments of the present invention, the present invention may contain Kanna, also known as sceletium tortuosum 1. In many embodiments of the present invention, Mesembrine is an alkaloid present in thematerial Sceletium tortuosum 1, also referred to herein as “Kanna”. In many clinical applications, it has been shown thatKanna 1 acts as a serotonin reuptake inhibitor (Ki=1.4 nM).1 More recently,Kanna 1 has also been found to behave as a weak inhibitor of the enzyme phosphodiesterase 4 (PDE4) (Ki=7,800 nM).2 As such, Mesembrine may contribute to the antidepressant effects ofKanna 3 1. The levorotary isomer, (−) mesembrine, is the natural form found inKanna 4 1, This material can provide benefits to the user of the present inventive e-liquid, including but not limited to mood-elevation. It also has anxiolytic properties. 1 Harvey, A. L.; Young, L. C.; Viljoen, A. M.; Gericke, N. P. (2011). “Pharmacological Actions of the South African Medicinal and Functional Food Plant Sceletium tortuosum and its Principal Alkaloids”. Journal of Ethnopharmacology 137 (3): 1124-1129.2 Id.3 Stafford, G. I.; Pedersen, M. E.; van Staden, J.; Jager, A. K. (October 2008). “Review on plants with CNS-effects used in traditional South African medicine against mental diseases”. Journal of Ethnopharmacology 119 (3): 513-537.4 Coggon, P.; Farrier, D. S.; Jeffs, P. W.; McPhail, A. T. (1970). “Absolute configuration of mesembrine and related alkaloids: X-ray analysis of 6-epimesembranol methiodide.” J. Chem. Soc. B: 1267-1271. -
FIG. 1 illustrates one additive of an embodiment of the present invention which is Blue Lotus 2 (Nymphaea caerulea). TheBlue Lotus 2 herb contains the alkaloids nuciferine and aporphine, which have a mildly sedating effect. This material can provide benefits to the user of the present inventive e-liquid including a relaxant effect. - Also shown in
FIG. 1 is the component Salvia (Salvia divinorum) 3. The known active constituent ofSalvia divinorum 3 is a trans-neoclerodane diterpenoid known as salvinorin A (chemical formula C23H28O8). This compound is present in the dried plant Salvia, at about 0.18% by volume5. Salvinorin A is not an alkaloid, (meaning it does not contain a basic nitrogen in its composition)6. In many natural applications,Salvia divinorum 3 synthesizes and excretes its active constituent (salvinorin A) via trichomes, of the peltate-glandular morphology, located just beneath the cuticle (subcuticular) layer of the plant7. Salvinorin A is considered a dissociative, which has a long history of use as an entheogen by indigenous Mazatec cultures8 (Valdés, 287). This material can provide a dissociative effect and pain-relief to the user of the present inventive e-liquid9. 5 Ott, Jonathan (1995). “Ethnopharmacognosy and Human Pharmacology of Salvia divinorum and Salvinorin A”. Curare 18 (1): 103-129. Retrieved 2007 Aug. 16.6 Giroud, C.; Felber F.; Augsburger M. (2000). “Salvia divinorum: an hallucinogenic mint which might become a new recreational drug in Switzerland”. Forensic Science International 112 (2): 143-150. doi:10.1016/S0379-0738(00)00180-8. PMID 10940599.7 Siebert, Daniel (2004). “Localization of Salvinorin A and Related Compounds in Glandular Trichomes of the Psychoactive Sage, Salvia divinorum”. Annals of Botany (Oxford University Press) 93 (6): 763-71.8 Valdés, Leander J. III; Diaz, José Luis; Paul, Ara G. (May 1983). “Ethnopharmacology of ska Maria Pastora (Salvia divinorum, Epling and Játiva-M)”. Journal of Ethnopharmacology 7 (3): 287-312.9 MacLean, Katherine; Johnson, Matthew; Reissig, Chad; Prisinzano, Thomas; Griffiths, Roland (8 Nov. 2012). “Dose-related Effects of Salvinorin A in Humans: Dissociative, Hallucinogenic, and Memory Effects”. National Center for Biotechnology Information. Retrieved 4 Sep. 2014. - As shown in
FIG. 1 , one additive of the present invention is Wild Dagga (Leonotis leonurus) 15. Leonotis leonurus 15, also known as lion's tail and wild dagga, is a plant species in the Lamiaceae (mint) family. The plant is a broadleaf evergreen large shrub native to South Africa and southern Africa, where it is very common. The main active component of Leonotis leonurus 15 is leonurine. This material can possess antinociceptive and anti-inflammatory properties while providing the user with mild euphoria and sedation10. As shown inFIG. 1 , one additive of the present invention is Kratom (Mitragyna speciosa) 5. There are more than 40 compounds in Mitragyna speciosa leaves, including many alkaloids such as mitragynine, mitraphylline, 7-hydroxymitragynine, and mitragynine pseudoindoxyl. Other active chemicals in M. speciosa include raubasine and some yohimbe alkaloids such as corynantheidine.Mitragyna speciosa 5 also contains at least one alkaloid (rhynchophylline) that is a calcium channel blocker, and reduces NMDA-induced current11. One analysis of products marketed as kratom leaf found, using liquid chromatography-electrospray ionization mass spectrometry (LC-ESI-MS), mitragynine at levels of 1-6% and 7-hydroxymirtrogynine at levels of 0.01-0.04%12. These compounds are thought to contribute to Mitragyna speciosa's 5 effects, including its use as an antidiarrheal as well as managing chronic pain13. The chemical structure of mitragynines incorporate the nucleus of the tryptamine, and the mitragynines may be responsible for the molecules which are observed in the serotonin and adrenergic systems. This material can provide benefits to the user of the present inventive e-liquid through its antidiarrheal and pain relief effects. 10 Ojewole J A (May 2005). “Antinociceptive, antiinflammatory and antidiabetic effects of Leonotis leonurus (L.) R. BR. [Lamiaceae] leaf aqueous extract in mice and rats”. Methods and Findings in Experimental and Clinical Pharmacology 27 (4): 257-64.11 Hendrickson, James B.; Sims, James J. (1963). “Mitragyna alkaloids: The structure of stipulatine”. Tetrahedron Letters 4 (14): 929.12 Kikura-Hanajiri, Ruri; Kawamura, Maiko; Maruyama, Takuro; Kitajima, Mariko; Takayama, Hiromitsu; Goda, Yukihiro (1 Jul. 2009). “Simultaneous analysis of mitragynine, 7-hydroxymitragynine, and other alkaloids in the psychotropic plant “kratom” (Mitragyna speciosa) by LC-ESI-MS”. Forensic Toxicology 27 (2): 67-74.13 Jansen, Karl L. R.; Colin J. Prast (1988 Jan. 4). “Ethnopharmacology of Kratom and the Mitragyna Alkaloids”. Journal of Ethnophamacology 23 (1): 115-119. - As shown in
FIG. 1 , one additive of the present invention is Celandine Poppy (Stylophorum diphyllum) 6, the common name is derived from greater celandine (Chelidonium majus), a closely related European plant with similarly shaped leaves and similarly colored and shaped flowers. This material can provide benefits to the user of the present inventive e-liquid through its flavor and taste. As shown inFIG. 1 , one additive of the present invention which is Mugwort (Artemisia) 7.Mugworts 7 are used medicinally, especially in Chinese, Japanese and Korean traditional medicine, and are used as an herb to flavor food. In Korea,Mugworts 7 were also used for plain, non-medicinal consumption; in South Korea,Mugworts 7, called Ssuk, are still used as a staple ingredient in many dishes including rice cakes and soup. This material can provide benefits to the user of the present inventive e-liquid by adding flavor and stimulation of circulation through pressure points in the body of a user. As shown inFIG. 1 , one additive of the present invention is Coltsfoot Leaf (Tussilago farfara) 8.Tussilago farfara 8 contains pyrrolizidine alkaloids. This material can provide benefits to the user of the present inventive e-liquid by providing alleviation for the respiratory tract as well as alleviation for general infections and colds14. 14 Sylvia Vogl, Paolo Picker, Judit Mihaly-Bison, Nanang Fakhrudin, Atanas G. Atanasov, Elke H. Heiss, Christoph Wawrosch, Gottfried Reznicek, Verena M. Dirsch, Johannes Saukel & Brigitte Koppa (2013). “Ethnopharmacological in vitro studies on Austria's folk medicine—an unexplored lore in vitro anti-inflammatory activities of 71 Austrian traditional herbal drugs”. Journal of Ethnopharmacology 149 (3): 750-771. - As shown in
FIG. 1 , one additive of the present invention is California Poppy (Eschscholzia californica) 9.California poppy 9 leaves were used medicinally by Native Americans, and the pollen was used cosmetically. The seeds are used in cooking15.California Poppy 9 contains the alkaloid Californidine (which is thought to be the primary constituent responsible for the effects of California Poppy 9)16. An aqueous extract of the plant has sedative and anxiolytic action17. This material can provide benefits to the user of the present inventive e-liquid including feelings of sedation and anxiety relief. Also shown inFIG. 1 is Sinicuichi (Heimia salicifolia) 10. Some isolated alkaloids found in Sinicuichi include Vertine, also known as cryogenine; it is regarded as the primary active component. Clinically demonstrated effects of Vertine include anticholinergic, anti-inflammatory, antispasmodic, hyperglycemic, hypotensive, sedative, tranquilizer, and vasodilator activity. This material can provide benefits to the user of the present inventive e-liquid including feelings of sedation. 15 California poppy, golden poppy, copa de oro”. Florida Museum of Natural History, University of Florida. Retrieved Apr. 9, 2012 16 Parfeinikov, S. A.; Murav'eva, D. A. (1983). “Eschscholzia californica alkaloids”. Khimiya Prirodnykh Soedinenii (2): 242-243.17 Rolland, A.; Fleurentin, J.; Lanhers, M. C.; Younos, C.; Misslin, R.; Mortier, F.; Mortier, J. M. (June 1991). “Behavioural Effects of the American Traditional Plant Eschscholzia Californica: Sedative and Anxiolytic Properties”. Planta Medica 57 (3): 212-216. - As shown in
FIG. 1 , one additive of the present invention is St. John's Wort (Hypericum perforatum) 11 abbreviated herein as “SJW”. Hyperforin and adhyperforin, two phloroglucinol constituents ofSJW 11, are TRPC6 receptor agonists and, consequently, they induce noncompetitive reuptake inhibition of monoamines (specifically, dopamine, norepinephrine, and serotonin), GABA, and glutamate when they activate this receptor in the brain. Hyperforin and adhyperforin inhibit reuptake of these neurotransmitters by increasing intracellular sodium ion concentrations. Moreover,SJW 11 is known to downregulate the β1 adrenoceptor and upregulate postsynaptic 5-HT1A and 5-HT2A receptors, both of which are a type of serotonin receptor. Other compounds may also play a role in SJW's 11 effects, such compounds include: oligomeric procyanidines, flavonoids (quercetin), hypericin, and pseudohypericin18. Hyperforin (the active ingredient) is also a powerful anti-inflammatory compound with anti-angiogenic, antibiotic, and neurotrophic properties19 SJW can provide benefits to the user of the present inventive e-liquid including anti-inflammatory and anti-depressive effects. 18 Nathan, P J (March 2001). “Hypericum perforatum (St John's Wort): a non-selective reuptake inhibitor? A review of the recent advances in its pharmacology”. Journal of psychopharmacology (Oxford, England) 15 (1): 47-54.19 “Biomedical Effects and Toxicity”. “Hyperforin”. Pubchem Compound. National Center for Biotechnology Information. - As shown in
FIG. 1 , one additive of the present invention is Yerba Lenna Yesca (Artemisia scoparia) 12. The chemical constituents ofYerba Lenna Yesca 12 may include: Capillarisin, Chlorogenic acid butyl ester; 6,7-Dimethylesculetin; Isosabandin; Magnolioside (isoscopoletin-13-D-glucopyranoside); 7-Methoxycoumarin; 7-Methylesculetin; Sabandin A; Sabandin B; Scoparone (6,7-dimethoxycoumarin); Scopoletin; β-Sitosterol20 . Artemisia scoparia 12 is an important traditional Chinese medicine. This material can provide benefits to the user of the present inventive e-liquid including its sedative effects. Also shown inFIG. 1 is Calea Zacatechichi (Calea ternifolia) 13. Chemical compounds isolated from this species may include flavones such as acacetin; and, sesquiterpene lactones such as germacranolides21. The sesquiterpenes known as caleicines and caleochromenes may be active in its effects on sleep. This material can provide benefits to the user of the present inventive e-liquid including its sleep remedy properties. Also shown inFIG. 1 is Leonurus sibiricus Flowers 14. Alkaloids isolated from Leonurus sibiricus include: Cycloleonurinine; Leoheterin; Leonurine; Leonurinine; Leuronurine; Prehispanolone; Preleoheterin; Stachydrine (“Leonurus sibiricus”). This material can provide benefits to the user of the present inventive e-liquid including relaxing effects. 20 Ali M S, Jahangir M, Saleem M (January 2003). “Structural distinction between sabandins A and B from Artemisia scoparia waldst. (Asteraceae)”. Nat. Prod. Res. 17 (1): 1-4.21 Lee, I. Y., et al. (1982). New germacranolides from Calea ternifolia and the molecular structure of 9α-Hydroxy-11, 13-Dihydro-11α, 13-Epoxyatripliciolide-8β-O-(2-Methylacrylate). Journal of Natural Products 45(3), 311-16. - As shown in
FIG. 1 , one additive of the present invention is Klip Dagga (Leonotis nepetifolia or L. nepetifolia) 16. L. nepetifolia (Klip Dagga) 16 is related to L. leonurus 15 (wild dagga or lion's tail.) L. nepetifolia's leaves are brewed as tea for fevers and coughs in Trinidad22. This material can provide benefits to the user of the present inventive e-liquid including a relaxing and anti-bacterial affect. Also shown inFIG. 1 is Damiana (Turnera diffusa) 17. Damiana 17 contains damianin; tetraphyllin B; gonzalitosin I; arbutin; tricosan-2-one; acacetin; p-cymene; β-sitosterol; 1,8-cineole; apigenin; α-pinene; β-carotene; β-pinene; eucalyptol; tannins; thymol; and hexacosanol.23 Damiana's 17 anxiolytic properties might be due to apigenin. It has also been shown that Damiana 17 may function as an aromatase inhibitor, which has been suggested as a possible method of action for its reputed effects.24 The chemical compound has long been claimed to have a stimulating effect on libido, supported by studies on sexual stimulation in mice25. This material can provide benefits to the user of the present inventive e-liquid including an increase in libido and relaxation. 22 Mendes, John. 1986. Cote ce Cote la: Trinidad & Tobago Dictionary, Arima, Trinidad, p. 135.23 Pharmacological evaluation of Bioactive Principle of Tumera aphrodisiaca, Indian Journal of Pharmaceutical Sciences, 2008,24 Zhao, J., Dasmahapatra, A. K., Khan, S. I., & Khan, I. A. (December 2008), Anti-aromatase activity of the constituents from damiana (Turnera diffusa), Journal of Ethnopharmacology 120: 387-393.25 Arletti, R., Benelli, A., Cavazzuti, E., Scarpetta, G., & Bertolini, A. (September 1998), Stimulating property of Turnera diffusa and Pfaffia paniculata extracts on the sexual behavior of male rats, Psychopharmacology 143: 15-19. - As shown in
FIG. 1 , one additive of the present invention is Kava (Piper methysticum) 18. Kava's 18 active principal ingredients are the kavalactones. Research has suggested that kavalactones potentiate GABAA activity, but do not alter levels of dopamine and serotonin in the CNS26. It is thought to do this via modulating GABA activity by altering the lipid membrane structure and sodium channel function27. Desmethoxyyangonin, one of the six major kavalactones, is a reversible MAO-B inhibitor (Ki 280 nM) and is able to increase dopamine levels in the nucleus accumbens. These findings might correspond to the slightly euphoric action ofkava 28 18. Kavain, in both enantiomeric forms, inhibits the reuptake of norepinephrine at the transporter (NAT), but not of serotonin (SERT)29. An elevated extracellular norepinephrine level in the brain may account for the reported enhancement of attention and focus. This material can provide to the user of the present inventive e-liquid including a euphoric effect with sedative properties in addition to increasing mental acuity. 26 Hunter, A (2006). “Kava (Piper methysticum) back in circulation”. Australian Centre forComplementary Medicine 2527 Teschke, Rolf; Qiu S X; Lebot V (2011). “Herbal hepatotoxicity by kava: Update on pipermethystine, flavokavain B and mould hepatotoxins as primarily assumed culprits”. Digestive and Liver Disease 43 (9): 676-681.28 Baum S S, Hill R, Rommelspacher H (October 1998). “Effect of kava extract and individual kavapyrones on neurotransmitter levels in the nucleus accumbens of rats”. Prog.Neuropsychopharmacol. Biol. Psychiatry 22.29 Seitz U, Schüle A, Gleitz J (December 1997). “[3H]-monoamine uptake inhibition properties of kava pyrones”. Planta Med. 63 (6): 548-9. - As shown in
FIG. 1 , one additive of the present invention is Scotch broom (Cytisus scoparius) 19. The characteristic constituents of Scotch broom 19 are biogenic amines (mostly tyramine in the young shoots), flavonoids (spiraeoside and scoparoside), isoflavones and their glycosides (genistin), as well as allelopathic quinolizidine alkaloids (mostly sparteine, lupanine, scoparin and hydroxy-derivatives), which defend the plant against insect infestation and herbivory (with the exception of the resistant Aphis cytisorum)30. This material adds flavoring and increased yellow color in the inventive e-liquid. Also shown inFIG. 1 is Valerian (Valeriana officinalis) 20. The known compounds detected inValerian 20 that may contribute to its method of action are: Alkaloids: actinidine, chatinine, shyanthine, valerianine, and valerine. Isovaleramide may be created in the extraction process; Gamma-aminobutyric acid (GABA); Isovaleric acid; Iridoids, including valepotriates: isovaltrate and valtrate.; Sesquiterpenes (contained in the Volatile oil): valerenic acid, hydroxyvalerenic acid and acetoxyvalerenic acid; and Flavanones: hesperidin, 6-methylapigenin and linarin31. Combined, these compounds are thought to provide the sedative and anxiolytic effects of the plant. This material can provide benefits to the user of the present inventive e-liquid including anti-anxiety and sedative effects. Also shown inFIG. 1 is Indian Warrior (Pedicularis densiflora) 21. In many applications,Indian warrior 21 is used as a tea or tincture to promote healthy immune function and its ability to relax tense muscles. The buds and flowers ofIndian Warrior 21 are often added to tea blends for their color, flavor, and relaxing properties. It is also found to be useful in the treatment of insomnia, as well as having antioxidant properties. This material can provide benefits to the user of the present inventive e-liquid including anti-anxiety and muscle relaxant effects. 30 Isamu Murakoshi, Yoshiaki Yamashita, Shigeru Ohmiya & Hirotaka Otomasu (1986). “(−)-3β-13α-dihydroxylupanine from Cytisus scoparius”. Phytochemistry 25 (2): 521-524.31 Fereidoon Shahidi and Marian Naczk, Phenolics in food and nutraceuticals (Boca Raton, Fla., USA: CRC Press, 2004), pp. 313-314. - As shown in
FIG. 1 , one additive of the present invention is Skullcap (Scutellaria lateriflora or S. lateriflora) 24. The principal phenolics in the leaves, stems, and roots of some Scutellaria species are baicalin, baicalein and wogonin. Baicalin has anti-inflammatory and analgesic effects in a rat model of thermal hyperalgesia32. A number of the flavones found in S. lateriflora 24 have been reported to selectively bind with high affinity to central benzodiazepine receptor sites, leading to the conclusion that the flavones exert anxiolytic and other benzodiazepine effects in rats33. This material can provide benefits to the user of the present inventive e-liquid including anti-anxiety effects. Also shown inFIG. 1 isLactuca virosa 22. Lactuce virosa contains flavonoids, coumarins, and N-methyl-β-phenethylamine. A variety of other chemical compounds have been isolated fromLactuce virosa 22. One of the compounds, lactucin, is an adenosine receptor agonist in vitro; while another, lactucopicrin, has been shown to act as an acetylcholinesterase inhibitor in vitro34. This material can provide the user of the present inventive e-liquid sedative effect benefits. Also shown inFIG. 1 is Red Clover (Trifolium pretense) 25.Trifolium pretense 25 is used in traditional medicine of India as deobstruent, antispasmodic, expectorant, sedative, anti-inflammatory, and antidermatosis agent35. This material can provide benefits to the user of the present inventive e-liquid including sedative effects. 32 Nishikawa, K., et al. (1999). Phenolics in tissue cultures of Scutellaria. Natural Medicines 53(4), 209-13.33 Medina, J. H., et al. (1997). Overview—Flavonoids: A new family of benzodiazepine receptor ligands. Neurochemical Research 22(4), 419-25.34 Rollinger, J M; Mocka, P; Zidorn, C; Ellmerer, E P; Langer, T; Stuppner, H (2005). “Application of the in combo screening approach for the discovery of non-alkaloid acetylcholinesterase inhibitors from Cichorium intybus”. Current drug discovery technologies 2 (3): 185-93.35 Wang L, Waltenberger B, Pferschy-Wenzig E M, Blunder M, Liu X, Malainer C, Blazevic T, Schwaiger S, Rollinger J M, Heiss E H, Schuster D, Kopp B, Bauer R, Stuppner H, Dirsch V M, Atanasov A G. Natural product agonists of peroxisome proliferator-activated receptor gamma (PPARγ): a review. Biochem Pharmacol. 2014 Jul. 29. - As shown in
FIGS. 2-4 , in one embodiment of the present invention, a herbal additive (distinct component) is presented in a 0.075 g per 1 mL ratio (7.5%) to the vaporizing liquid. In one embodiment of the present invention there is a fluid mixture, preferably, vegetable glycerin and/or propylene glycol mixture (common vaporizing solution) in a ratio of roughly 92%. In one embodiment of the present invention the fluid flavoring comprises 0.5% of the gross volume of e-liquid. - In one embodiment of the present invention, as shown in
FIG. 2-4 , the procedure for making the composition is as follows. Herbal additive is mixed with vegetable glycerin and/or propylene glycol solution. In several embodiments of the present invention the mixing can be done at room temperature, heated or cooled in the ranges of −50 to 150° F. In several embodiments of the present invention the blending can be done by using simple mixing up to using an industrial blender as is used in the art. In many embodiments of the delivery systems for the present invention includes: electronic vaporizing, electronic cigarette, personal vaporizer, or other vaporizing methods known in the art. Certain examples of successful mixtures include, but are not limited to, mixture A 200 (which containsWild Lettuce 22, Wild Dagga 15,Indian Warrior 21,Kava 18,Valerian 20, and Kratom 5) that has a relaxing and headache/pain-diminishing effect caused by the alkaloids in these herbs that is distinct and unique in terms of ingredients and purpose compared to other e-liquid patents. Mixture B 300 (FIG. 3 ) (which containsWild Lettuce 22,Kratom 5,Skullcap 24,Kanna 18,Sinicuichi 10,Klip Dagga Leaf 16, and Blue Lotus 2) that causes a sedated feeling with relaxation and assists in sleeping. Mixture C 400 (FIG. 4 ) (which contains Leonurus sibericus 14,California Poppy 9, Yerba lenna yesca 12, Calea zacatechichi 13,hernia salicifolia 10, Damiana 17, and Celandine poppy 6) that causes a euphoric feeling with alertness. Although different mixtures using the Herb Additives as the base ‘active compounds are envisioned by the present invention. - As shown in
FIG. 2 , in one embodiment of the present invention,Mixture A 200, a compound is created from a mixture of extracts from different herbs and components. These herbal extracts can come in various forms including a powdered form, crushed leaf form, as well as liquid form (tincture formed from herbs in a water or alcohol base). In one embodiment, the product consists of different mixtures of herbal extracts to form different Herbal Additives. InMixture A 200, thecompound 210 consists of 25% Wild Lettuce Indian Warrior % Kava % Valerian % Kratom 5. Percentage composition is by weight in many embodiments, but can be in portions of volume or other measurements. The herbal additive is blended with a vaporizing solution. The vaporizing solution generally consists of a 50/50 blend of vegetable glycerin and propylene glycol (however the vaporizing solution can be any ratio of vegetable glycerin and propylene glycol). The herbal additive is then added to the vaporizing solution at a ratio of 0.075 g to 1 mL (although this ratio can vary from 0.001 to 2.0 g). The solution (consisting of the Herbal Additive and vaporizing solution) is blended using an industrial blender, or any other blending mechanism suitable in the art for e-liquids. The blending is typical done at slightly warmer than room temperature, but the blending can occur in temperatures between −50-150° F. 220. This blend is strained over a type of filter to collect the powder residue filters known in the art, other filters such as coffee filters can be used. The resulting powder-less solution is the final blend ofMixture A 200, which is put into a container for sales to an end user. The final blend is preferably consumed using vapor products (electronic cigarette, electronic vape pen, any device that vaporizes liquid into a smokeable vapor for the user) 230. - As shown in
FIG. 3 , in Mixture B 300, thecompound 310 consists of 20% Wild Lettuce, 20% Kratom 5, 15% Skullcap 24, 15% Kanna % Sinicuichi Klip Dagga Leaf % Blue Lotus 2. The herbal additive is blended with a vaporizing solution. The vaporizing solution generally consists of a 50/50 blend of vegetable glycerin and propylene glycol (however the vaporizing solution can be any ratio of vegetable glycerin and propylene glycol). The herbal additive is then added to the vaporizing solution at a ratio of 0.075 g to 1 mL (although this ratio can vary from 0.001 to 2.0 g). The solution (consisting of the Herbal Additive and vaporizing solution) is blended using an industrial blender, or any other blending mechanism suitable in the art for e-liquids. The blending is typically done at slightly warmer than room temperature, but the blending can occur in temperatures between −50-150° F. 320. This blend is strained over a type of filter to collect the powder residue filters known in the art, filters such as coffee filters can be used. The resulting powder-less solution is the final blend of Mixture B, which is put into a container for sales to an end user. The final blend is preferably consumed using vapor products (electronic cigarette, electronic vape pen, any device that vaporizes liquid into a smokeable vapor for the user) 330. - As shown in
FIG. 4 , inMixture C 400, thecompound 410 consists of 20% Leonurus sibericus 14, 20% California Poppy % Calea zacatechichi % Damiana 17, and 10% Celandine Poppy 6. The herbal additive is blended with a vaporizing solution. The vaporizing solution generally consists of a 50/50 blend of vegetable glycerin and propylene glycol (however the vaporizing solution can be any ratio of vegetable glycerin and propylene glycol). The herbal additive is then added to the vaporizing solution at a ratio of 0.075 g to 1 mL (although this ratio can vary from 0.001 to 2.0 g). The solution (consisting of the Herbal Additive and vaporizing solution) is blended using an industrial blender, or any other blending mechanism suitable in the art for e-liquids. The blending is typically done at slightly warmer than room temperature, but the blending can occur in temperatures between −50-150° F. 420. This blend is strained over a type of filter to collect the powder residue filters known in the art, other filters such as coffee filters can be used. The resulting powder-less solution is the final blend of Mixture C, which is put into a container for sales to an end user. The final blend is preferably consumed using vapor products (electronic cigarette, electronic vape pen, any device that vaporizes liquid into a smokeable vapor for the user) 430. - As shown in
FIG. 5 , in one embodiment of the present invention, when the e-liquid is tested in laboratory conditions, it does not contain, or emit any substances that are controlled, or banned under current Federal and/or state regulations concerningsuch substances 500. - Although several preferred embodiments of the present invention have been described in detail herein, the invention is not limited hereto. It will be appreciated by those having ordinary skill in the art that various modifications can be made without materially departing from the novel and advantageous teachings of the invention. Accordingly, the embodiments disclosed herein are by way of example. It is to be understood that the scope of the invention is not to be limited thereby.
Claims (9)
1. An electronic cigarette liquid comprising:
a vaporizing base mixed with a herbal powder extract.
2. The vaporizing base of claim 1 further comprising:
said vaporizing base is a propylene glycol.
3. The vaporizing base of claim 1 further comprising:
said vaporizing base is a vegetable glycerin.
4. The vaporizing base of claim 1 further comprising:
said vaporizing base is a vegetable glycerin and propylene glycol.
5. The vaporizing base and herbal powder extract of claim 1 further comprising:
said vaporizing base is mixed with said herbal powder extract at a 0.001.001-2.0 g per 1 mL ratio.
6. The herbal extract of claim 1 further comprising said herbal extract may include members selected from the group of materials consisting of Kanna (sceletium tortuosum), Blue lotus (Nymphaea caerulea), Salvia (Salvia divinorum), Kratom (Mitragyna speciosa), Celandine poppy (Stylophorum diphyllum), Mugwort (Artemisia), Coltsfoot leaf (Tussilago farfara), California poppy (Eschscholzia californica), Sinicuichi (Heimia salicifolia), St. John's Wort (Hypericum perforatum), Yerba lenna yesca (Artemisia scoparia), Calea zacatechichi (Calea ternifolia), Leonurus sibericus (Leonurus sibiricus), Wild dagga (Leonotis leonurus), Klip dagga (Leonotis nepetifolia), Damiana (Turnera diffusa), Kava (Piper methysticum), Scotch broom tops (Cytisus scoparius), Valarien (Valeriana officinalis), Indian warrior (Pedicularis densiflora), Wild lettuce (Lactuca virosa), Skullcap (Scutellaria lateriflora), Red Clover (Trifolium pretense), and/or combinations therein.
7. A method for creating an electronic cigarette liquid comprising the steps of:
mixing an herbal additive with a vaporizing base wherein said base is comprised of vegetable glycerin, propylene glycol solution and/or combination of the two.
8. The method of claim 7 in further comprising the step of:
mixing said herbal additive and said vaporizing base at temperature between 0 and 50 degrees Celsius.
9. The method of claim 7 in further comprising the step of:
forming the herbal additive from a group that may include members selected from the group of materials consisting of Kanna (sceletium tortuosum), Blue lotus (Nymphaea caerulea), Salvia (Salvia divinorum), Kratom (Mitragyna speciosa), Celandine poppy (Stylophorum diphyllum), Mugwort (Artemisia), Coltsfoot leaf (Tussilago farfara), California poppy (Eschscholzia californica), Sinicuichi (Heimia salicifolia), St. John's Wort (Hypericum perforatum), Yerba lenna yesca (Artemisia scoparia), Calea zacatechichi (Calea ternifolia), Leonurus sibericus (Leonurus sibiricus), Wild dagga (Leonotis leonurus), Klip dagga (Leonotis nepetifolia), Damiana (Turnera diffusa), Kava (Piper methysticum), Scotch broom tops (Cytisus scoparius), Valarien (Valeriana officinalis), Indian warrior (Pedicularis densiflora), Wild lettuce (Lactuca virosa), Skullcap (Scutellaria lateriflora), Red Clover (Trifolium pretense), and/or combinations therein.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14/581,179 US20160174603A1 (en) | 2014-12-23 | 2014-12-23 | Electronic Vapor Liquid Composition and Method of Use |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14/581,179 US20160174603A1 (en) | 2014-12-23 | 2014-12-23 | Electronic Vapor Liquid Composition and Method of Use |
Publications (1)
Publication Number | Publication Date |
---|---|
US20160174603A1 true US20160174603A1 (en) | 2016-06-23 |
Family
ID=56127959
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/581,179 Abandoned US20160174603A1 (en) | 2014-12-23 | 2014-12-23 | Electronic Vapor Liquid Composition and Method of Use |
Country Status (1)
Country | Link |
---|---|
US (1) | US20160174603A1 (en) |
Cited By (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106490674A (en) * | 2016-11-30 | 2017-03-15 | 湖北中烟工业有限责任公司 | A kind of electronics tobacco tar of fresh breath and preparation method thereof |
CN106723301A (en) * | 2016-12-19 | 2017-05-31 | 深圳瀚星翔科技有限公司 | Tobacco juice for electronic smoke |
CN106912982A (en) * | 2017-01-20 | 2017-07-04 | 深圳瀚星翔科技有限公司 | A kind of electronic cigarette tobacco tar and preparation method thereof |
WO2018031600A1 (en) * | 2016-08-08 | 2018-02-15 | Juul Labs, Inc. | Nicotine oxalic acid formulations |
WO2018212727A3 (en) * | 2016-09-29 | 2019-01-03 | Goermez Salih | Double filtered smoking-cessation aid nicotine-free herbal cigarette |
CN109549246A (en) * | 2019-01-18 | 2019-04-02 | 薪火高科(深圳)有限公司 | A kind of tobacco juice for electronic smoke and preparation method thereof of adjustable function of human body |
WO2019157526A1 (en) * | 2018-02-12 | 2019-08-15 | TPRX Tech, LLC | Liquid vape base and extraction process |
CN111387541A (en) * | 2020-04-30 | 2020-07-10 | 铂德(深圳)科技有限公司 | Watermelon extract solution, watermelon electronic cigarette oil and preparation method thereof |
WO2021102653A1 (en) * | 2019-11-25 | 2021-06-03 | 深圳雾芯科技有限公司 | E-liquid |
WO2021102652A1 (en) * | 2019-11-25 | 2021-06-03 | 深圳雾芯科技有限公司 | E-liquid |
CN113854620A (en) * | 2021-09-02 | 2021-12-31 | 深圳市艾普生物科技有限公司 | Electronic cigarette liquid additive and preparation method and application thereof |
CN113854623A (en) * | 2021-10-28 | 2021-12-31 | 中科分子生物(广东)股份有限公司 | Herbal low-temperature atomized electronic cigarette tobacco tar free of nicotine salt |
US11510433B2 (en) | 2013-12-05 | 2022-11-29 | Juul Labs, Inc. | Nicotine liquid formulations for aerosol devices and methods thereof |
WO2023076533A1 (en) * | 2021-10-29 | 2023-05-04 | Sensorium Therapeutics, Inc. | Solid forms of mesembrine and therapeutic uses thereof |
WO2023150361A1 (en) * | 2022-02-04 | 2023-08-10 | Botanic Tonics, LLC | Kava compositions and methods of making same |
US20230364172A1 (en) * | 2022-05-14 | 2023-11-16 | Syncotrance, LLC | Modulation of solubility, palatability, absorption, and bioavailability of mitragyna speciosa-derived compounds for oral and buccal delivery |
WO2023230049A1 (en) * | 2022-05-23 | 2023-11-30 | Sensorium Therapeutics, Inc. | Solid forms of mesembrine and therapeutic uses thereof |
US12156533B2 (en) | 2013-05-06 | 2024-12-03 | Juul Labs, Inc. | Nicotine salt formulations for aerosol devices and methods thereof |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20130298905A1 (en) * | 2012-03-12 | 2013-11-14 | UpToke, LLC | Electronic vaporizing device and methods for use |
US20140144429A1 (en) * | 2012-11-28 | 2014-05-29 | E-Nicotine Technology, Inc. | Methods and devices for compound delivery |
US20170119981A1 (en) * | 2014-06-30 | 2017-05-04 | Syqe Medical Ltd. | Flow regulating inhaler device |
-
2014
- 2014-12-23 US US14/581,179 patent/US20160174603A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20130298905A1 (en) * | 2012-03-12 | 2013-11-14 | UpToke, LLC | Electronic vaporizing device and methods for use |
US20140144429A1 (en) * | 2012-11-28 | 2014-05-29 | E-Nicotine Technology, Inc. | Methods and devices for compound delivery |
US20170119981A1 (en) * | 2014-06-30 | 2017-05-04 | Syqe Medical Ltd. | Flow regulating inhaler device |
Non-Patent Citations (4)
Title |
---|
Herbal Shop, "Herbal e Liquid (e Juice)", Published 8/3/2013, accessed 8/30/2017. * |
Herbal Shop, "The rise of herbal eJuice", Published 9/22/2013, accessed 8/30/2017. * |
Lide, D.R., Handbook of Chemistry and Physics, 2007-2008, CRC Press, p. 3-444 * |
Rochester Institute of Technology, "Density of Glycerin-Water Solutions", accessed 8/30/2017 * |
Cited By (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US12156533B2 (en) | 2013-05-06 | 2024-12-03 | Juul Labs, Inc. | Nicotine salt formulations for aerosol devices and methods thereof |
US11510433B2 (en) | 2013-12-05 | 2022-11-29 | Juul Labs, Inc. | Nicotine liquid formulations for aerosol devices and methods thereof |
US12167744B2 (en) | 2013-12-05 | 2024-12-17 | Juul Labs, Inc. | Nicotine liquid formulations for aerosol devices and methods thereof |
US11744277B2 (en) | 2013-12-05 | 2023-09-05 | Juul Labs, Inc. | Nicotine liquid formulations for aerosol devices and methods thereof |
WO2018031600A1 (en) * | 2016-08-08 | 2018-02-15 | Juul Labs, Inc. | Nicotine oxalic acid formulations |
WO2018212727A3 (en) * | 2016-09-29 | 2019-01-03 | Goermez Salih | Double filtered smoking-cessation aid nicotine-free herbal cigarette |
CN106490674A (en) * | 2016-11-30 | 2017-03-15 | 湖北中烟工业有限责任公司 | A kind of electronics tobacco tar of fresh breath and preparation method thereof |
CN106723301A (en) * | 2016-12-19 | 2017-05-31 | 深圳瀚星翔科技有限公司 | Tobacco juice for electronic smoke |
CN106912982A (en) * | 2017-01-20 | 2017-07-04 | 深圳瀚星翔科技有限公司 | A kind of electronic cigarette tobacco tar and preparation method thereof |
WO2019157526A1 (en) * | 2018-02-12 | 2019-08-15 | TPRX Tech, LLC | Liquid vape base and extraction process |
AU2019218399B2 (en) * | 2018-02-12 | 2024-11-07 | TPRX Tech, LLC | Liquid vape base and extraction process |
US11957786B2 (en) | 2018-02-12 | 2024-04-16 | TPRX Tech, LLC | Liquid vape base and extraction process |
CN109549246A (en) * | 2019-01-18 | 2019-04-02 | 薪火高科(深圳)有限公司 | A kind of tobacco juice for electronic smoke and preparation method thereof of adjustable function of human body |
WO2021102652A1 (en) * | 2019-11-25 | 2021-06-03 | 深圳雾芯科技有限公司 | E-liquid |
WO2021102653A1 (en) * | 2019-11-25 | 2021-06-03 | 深圳雾芯科技有限公司 | E-liquid |
CN111387541A (en) * | 2020-04-30 | 2020-07-10 | 铂德(深圳)科技有限公司 | Watermelon extract solution, watermelon electronic cigarette oil and preparation method thereof |
CN113854620A (en) * | 2021-09-02 | 2021-12-31 | 深圳市艾普生物科技有限公司 | Electronic cigarette liquid additive and preparation method and application thereof |
CN113854623A (en) * | 2021-10-28 | 2021-12-31 | 中科分子生物(广东)股份有限公司 | Herbal low-temperature atomized electronic cigarette tobacco tar free of nicotine salt |
WO2023076533A1 (en) * | 2021-10-29 | 2023-05-04 | Sensorium Therapeutics, Inc. | Solid forms of mesembrine and therapeutic uses thereof |
WO2023150361A1 (en) * | 2022-02-04 | 2023-08-10 | Botanic Tonics, LLC | Kava compositions and methods of making same |
US20230364172A1 (en) * | 2022-05-14 | 2023-11-16 | Syncotrance, LLC | Modulation of solubility, palatability, absorption, and bioavailability of mitragyna speciosa-derived compounds for oral and buccal delivery |
WO2023230049A1 (en) * | 2022-05-23 | 2023-11-30 | Sensorium Therapeutics, Inc. | Solid forms of mesembrine and therapeutic uses thereof |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20160174603A1 (en) | Electronic Vapor Liquid Composition and Method of Use | |
Verma et al. | Plants used as antihypertensive | |
Ingale et al. | Pharmacological studies of Passiflora sp. and their bioactive compounds | |
Shi et al. | Herbal insomnia medications that target GABAergic systems: a review of the psychopharmacological evidence | |
Gomes et al. | Plants with neurobiological activity as potential targets for drug discovery | |
Metwally et al. | Monograph of Psidium guajava L. leaves | |
Brunetti et al. | Pharmacology of herbal sexual enhancers: a review of psychiatric and neurological adverse effects | |
Sengupta et al. | Plant-derived natural products for Parkinson’s disease therapy | |
Rahman et al. | A review: pharmacognostics and pharmacological profiles of Nardastachys jatamansi DC | |
Saroya et al. | Pharmacotherapeutic potential of natural products in neurological disorders | |
Lopes et al. | Neurobehavioral and toxicological activities of two potentially CNS-acting medicinal plants of Piper genus | |
da Silva et al. | Phytochemistry of some Brazilian plants with aphrodisiac activity | |
Lanje et al. | Medicinal natural drug of Valerian (Valerina Officinalis): an-over review | |
Lone et al. | Phytochemical analysis of clove (Syzygium aromaticum) dried flower buds extract and its therapeutic importance | |
Porres-Martínez et al. | Pharmacological activity of Salvia lavandulifolia and chemical components of its essential oil. A review | |
Das et al. | Bioactivity-guided fractionation and identification of bioactive molecules: A basic method in drug discovery | |
Niero et al. | Medicinal plants and phytomedicines | |
Iyekowa et al. | High-Performance Liquid Chromatography (HPLC) profile and anxiolytic activity of hexane extract of Datura metel leaves extract in balb/c mice | |
Saroya et al. | Psychoactive medicinal plants and fungal neurotoxins | |
Konrath et al. | Plants with anti-addictive potential | |
Timotius et al. | Major bioactive compounds of pilis plant materials: A GC-MS analysis | |
Iyekowa et al. | Phytoconstituents, Acute Toxicity and In-Vivo Anti-anxiety Activity of Chloroform and Ethylacetate Extracts of Datura Stramonium in Balb/C Mice | |
Olusa et al. | Acute toxicity test and behavioural activity of aqueous and ethanol dried leaf extracts of Solenostemon monostachyus in mice | |
Malathi et al. | Study on preliminary phytochemicals and GC-MS analysis of Justicia adhatoda leaves extract | |
Chaachouay et al. | Chambá (Justicia pectoralis Jacq. Acanthaceae) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: INNOVATIVE HERBAL BLENDS, LLC, FLORIDA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:ABAYARATHNA, SAHAN;JAEHNE, MICHAEL;SIGNING DATES FROM 20170808 TO 20170809;REEL/FRAME:043253/0772 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |